Soft Tissue and Bone Sarcoma Group, 25th Anniversary Meeting on Sarcomas, April 5–7, 2001, Aarhus, Denmark by Gibbs, John
Correspondence to: John Gibbs, M.D., Division of Surgery, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263,
USA. Tel: (+1) 716 845 5807; Fax: (+1) 716 845 3434, E-mail: john.gibbs@roswellpark.org
1357–714X print/1369–1643 online/01/030157–28 © 2001 Taylor & Francis Ltd
DOI: 10.1080/135771401200XXXXX
Sarcoma (2001) 5, 157–184
EORTC ABSTRACTS
Soft Tissue and Bone Sarcoma Group, 25th 
Anniversary Meeting on Sarcomas, April 5–7, 2001, 
Aarhus, Denmark
The Soft Tissue and Bone Sarcoma Group of EORTC was founded in 1976 and has since developed into one of the leading cooperative
groups in the research of sarcomas and has members from 40 institutions in 14 countries. So far it has conducted more than 40 clinical trials
with more that 250 patients included per year. In addition a database with more than 2500 patients has been developed.
The activities of the group have primarily been within the areas of standards for local as well as systemic treatment strategies, new drug
development and quality control procedures. The group has an extensive quality control programme involving a strict membership policy,
central reviews of responses and pathology, use of a systemic therapy checklist and on-site monitoring of studies.
At the 25th Anniversary Meeting attention was focused on the future of sarcomas with special attention to new developments in the field of
molecular biology and cytogenetics, imaging as well as local and systemic treatment. Posters covering all areas of sarcomas were presented.
Unfortunately one of our most loyal members over many years, Alberto Azzarelli, died on 22, February 2001 after several months of
suffering. He was not only an important member of the scientific committee of this meeting but for many years a very active and inspiring
member of EORTC STBSG and his entire professional life was dedicated to sarcomas. The entire group misses Alberto, but we hope, that
in his spirit, we continue the effort to improve the care of patients with sarcomas and therefore we dedicate the 25th Anniversary Meeting
to his memory.
We were very pleased that 240 participants joined the meeting and that 85 abstracts were submitted—many more than anticipated—clearly
demonstrating the increasing interest in the field.
In general the meeting was very successful and the following abstracts were presented.
Ole Steen Nielsen, Chairman
SCIENTIFIC PROGRAM
THURSDAY 5 APRIL 2001
8.00–9.00 Registration and poster mounting
9.00–9.15 Welcome and Introduction: The past 25-year of
EORTC  Soft  Tissue  and  Bone  Sarcoma  Group.
(SI)
A.T. van Oosterom, Leuven
9.15–10.40 Trial design in sarcomas.
Chairmen: F. van Coevorden & O.M. Jensen
9.15–9.40 Future  clinical  trial  design  of  sarcoma  studies?
(S2)
J. Verweij, Rotterdam
9.40–10.05 How should we measure treatment effects: Progres-
sion-free survival as the primary endpoint? (S 3)
M. van Glabbeke, Bruxelles




11.00–12.30 How  will  molecular  biology and  cytogenetics
help the sarcoma clinicians?
Chairmen: Pancras Hogendoorn & S. Daugaard
11.00–11.30 Molecular biology and cytogenetics in diagnosis of
sarcomas. (S 5)
C. Cooper, London
11.30–12.00 Any role left for sarcoma pathology? (S 6)
C.D.M. Fletcher, Boston
12.00–12.30 What difference will molecular biology and cytoge-
netics make to future trials and treatments? (S 7)
L. Helman, Bethesda
12.30–14.00 Lunch and Poster viewing.
14.00–15.00 What is the best strategy for imaging of sarco-
mas?
Chairmen: A.G. Jurik & L. Svancorova
14.00–14.20 MR imaging of sarcomas? (S 8)
A.M. De Schepper, Edegem
14.20–14.40 Future  role  of  PET  in  diagnostics  and  response
evaluation of sarcomas? (S 9)
S. Stroobants, Leuven
14.40–15.0 Local and distant staging of bone and soft tissue sar-
comas—How good are we? (S10)
A. Saiffuddin, Middlesex
15.05–16.05 Future role of local treatment of soft tissue sar-
comas.
Chairmen: A.N. van Geel & J. Keller158 EORTC Abstracts
15.05–15.25 Which  surgical  questions  need to be answered in
future studies? (S 11)
R.J. Grimer, Birmingham
15.25–15.45 Which  questions  in  radiotherapy  need  to  be
answered in future studies? (S 12)
B. O’Sullivan, Toronto
15.45–16.05 Is consensus possible? General discussion.
P. Hohenberger, Berlin
16.05–16.30 Coffee break.
16.30–17.30 Potential  role  of  new  treatment  options  for
locally advanced soft tissue sarcomas?
Chairmen: H.J. Hoekstra & S. Bonvalot
16.30–16.50 Any role of TNF-perfusion outside the few dedi-
cated centres? (S 13)
F. Lejeune, Lausanne
16.50–17.10 Prospective  role  of  chemotherapy  combined  with
hyperthermia in sarcomas? (S 14)
R. Issels, Munich
17.10–17.30 Why have these new local treatments not become
more widespread? General discussion. (S 15)
M.H. Robinson, Sheffield
18.45–20.00 SOCIAL PROGRAM: Guided bus tour to ‘The
Old Town’ of Aarhus.
20.00–23.30 Conference Dinner: Restaurant Prins Ferdinand
FRIDAY 6 APRIL 2001
9.00–10.30 What should be the  future strategy for adju-
vant chemotherapy in soft tissue sarcomas?
Chairmen: W.P. Steward & P. Woll
9.00–9.10 Adjuvant  chemotherapy  has  no  effect  on  sur-
vival—the EORTC experience. (S 16)
V. Bramwell, London Ontario
9.10–9.20 Adjuvant chemotherapy may improve survival—the
Italian experience. (S 17)
S. Frustaci, Aviano
9.20–9.40 Pro adjuvant treatment outside clinical trial. (S 18)
R.S. Benjamin, Houston
9.40–10.00 Contra adjuvant treatment outside clinical trial. (S
19)
K. Antman, New York
10.00–10.15 How to proceed?
V. Bramwell, London Ontario
10.15–10.30 General discussion.
10.30–11.00 Coffee break.
11.00–12.00 Systemic  treatment  of  advanced  soft  tissue
sarcomas.
Chairmen: P. Reichardt & J.Y. Blay
11.00–11.20 Is  Doxorubicin  really  the  standard  treatment  of
advanced soft tissue sarcomas? (S 20)
T. Alvegaard, Lund
11.20–11.40 New drugs for treatment  of metastatic  soft  tissue
sarcomas? (S 21)
A. le Cesne, Paris
11.40–12.00 How to proceed? General discussion.
P. Reichardt, Berlin; J.Y. Blay, Lyon
12.00–13.30 Lunch and Poster viewing.
13.30–14.30 Poster discussion
Chairmen: J.A. Radford & R.B. Keus
14.30–15.30 What is  the  optimal treatment of the Ewing/
PNET family of tumours?
Chairmen: I. Judson & H. Jürgens
14.30–14.50 The experience of SFOP. (S 22)
O. Oberlin, Paris
14.50–15.10 What did we learn from the EICESS studies? (S 23)
H. Jürgens, Münster
15.10–15.30 The SSG/Italian Group strategy. (S 24)
P. Picci, Bologna
15.30–15.45 After Euro-Ewing 99—any questions left? General
discussion.
I. Judson, London; H. Jürgens, Münster
15.45–16.00 Closing of meeting.
O.S. Nielsen, Aarhus
16.00–16.30 Coffee break. End of scientific meeting.
16.30–17.30 Subcommittee Meetings of EORTC STBSG:
17.30–18.30 Business meeting of STBSG.
18.30–20.15 General meeting of STBSG.
21.00– Dinner for members of EORTC STBSG. Restau-
rant ‘Queens Garden’.
SATURDAY 7 APRIL 2001
09.00–13.00 General meeting of STBSG (cont.).
incl. coffee break
13.00–14.00 Lunch. End of Meeting
Abstracts—Invited Speakers
The past 25 years of EORTC soft tissue and bone sarcoma
group
A. VAN OOSTEROM
(Department of Oncology, U.Z. Gasthuisberg, KU Leuven, Leuven)
Preliminary meetings in April—to June 1976—between founding
members  led  to  the  full  development  of  a  protocol  in  which
CyVADic was compared with CyV-Adic in advanced soft tissue
sarcoma. This protocol was approved by the  EORTC Protocol
Review Committee and the Group received the number 62 and the
protocol 62761.
The first and founding meeting of the Group was held in Zurich
(Switzerland)  in  September  1976  where  G.  Bonadonna
(Milan—Italy)  was  elected  chairman  and  H.M.  Pinedo
(Utrecht—The Netherlands), the driving force, became secretary.
The protocol was initiated  and in October the first  patient had
been registered. Pinedo was the study co-ordinator.
Other founding members came from France, Germany, Belgium,
Switzerland, the UK and the Netherlands.
The objectives of the Group were to develop, stimulate and co-ordi-
nate studies on all aspects of the treatment of soft tissue sarcomas
within the framework of the European Organisation for Research
and Treatment of Cancer. The second objective was to organise
congresses, symposia and conferences to promote these studies.
The first adjuvant study in which after optimal local treatment the
patients were randomised to no treatment or adjuvant CyVADic,
started  late  1977  and  was  co-ordinated  by  V.  Branwell
(Manchester—UK).EORTC Abstracts 159
In 1978 the soft tissue sarcoma group merged with the interna-
tional  osteo-sarcoma  working  party  to  form  the  EORTC  Soft
Tissue and Bone Sarcoma Group (STBSG).
The emphasis in the studies has always remained the treatment in
first and second line of advanced soft tissue sarcoma patients. It
has led to a priceless collection of data in Brussels of over 3.000
patients stored under the careful guidance of R. Sylvester and since
1989 of M. Van Glabbeke, the Group’s statisticians.
Next to the study of many new agents, the Group has developed
very strict quality control procedures and played a major role in the
development of the RECIST criteria.
In the recent past studies in Ewing sarcoma and several subtypes
of soft tissue sarcomas have been initiated. It should be mentioned
that the international recognition of this Group has led to a track
record of at least one oral presentation at every ASCO and ECCO-
ESMO meeting since 1984. Of course major publications, not only
in books, but also in the Journal of Clinical Oncology, the Euro-
pean  Journal  of  Cancer,  the  Annals  of  Oncology,  the  British
Journal of Cancer and the Journal of the National Cancer Institute
but also in the New England Journal of Medicine and the Lancet
have appeared.
The future looks bright: in view of the fact that the Group plays a
pivotal role not only in the clinical development of the new molec-
ular targeted therapies but also performs translational research in
its present studies. The number of participating institutions and
countries will certainly increase in the next decades.
Future clinical trial design of soft tissue sarcoma studies
J. VERWEIJ
(Rotterdam Cancer Institute and University Hospital, 3075 EA Rotter-
dam, The Netherlands)
Until recently most soft tissue sarcomas, due to the relatively low
incidence of these diseases, have been treated and studied grouped
together as if they were one disease. Retrospective analyses of large
databases have however identified  certain subtypes that tend to
respond  differently  from  others  and  the  increased  knowledge
should guide us to a better differentiated trial design.
In addition, due to the increased knowledge of molecular biology
and the improved molecular diagnostics more and more specific
receptors on the cell surface have been identified that can be used
as targets for anticancer treatment. Frequently these receptors are
specifically overexpressed in specific subtypes of sarcomas and this
increasing knowledge should also lead to a more targeted treat-
ment. Inhibitors of these more selective targets are currently in
development.  Examples  are  inhibitors  of  signal  transduction,
inhibitors of farnesyltransferase and inhibitors of angiogenesis or
matrix  metallo  proteinase.  Importantly,  many  of  these  latter
agents, in in vitro and in vivo models, mainly exhibit growth inhi-
bition rather than tumour regression. This aspect is also important
to take into account when designing a trial. If tumour regression
can not be expected, phase II studies seem rather useless. Once
time to progression and/or survival become the main endpoint, the
phase IIB or preferably phase III trial design becomes the preferred
one. Obviously, moving from phase I directly to phase II would
involve a giant leap of faith. Intermittent alternative trial designs
are therefore currently under consideration.
Whatever the issue, it is clear that in the near future we will more
and more witness the design of large trials as well as the design of
trials  in  specific  subtypes  of  sarcomas  or  even  a  more  general
approach of  targeting  a molecular  target  regardless  of subtype.
Examples of these are the potential use of conventional cytotoxics
such  as  Taxol  for  angiosarcomas  or  Ifosfamide  in  synovial
sarcomas, but also the more recently developed agents, such as
STI  571  in  C-kit  overexpressing  sarcomas  or  agents  directly
towards  the  ppar-   ligand  in  liposarcomas.  The  specificities  of
these trial designs will be discussed in detail.
How should we measure treatment effects: progression free
survival as the primary end-point?
M. VAN GLABBEKE
(EORTC Data Center, Brussels, Belgium)
Introduction: The aim of this presentation is to explore whether
and when we can recommend progression free survival as the prin-
cipal end-point for phase II trials on soft tissue sarcoma.
For  which  agents? Response  to  therapy,  based  on  measured
decrease in the size of cancer lesions, is the most effective end-
point  to  document  biologic  anticancer  activity  of cytoreductive
agents and consequently to identify potential new cytoreductive
drugs. The RECIST criteria  provide an harmonized method of
response  evaluation.  For  non  cytoreductive  anticancer  agents,
biologic  activity  is  not  expected  to  translate  into  shrinkage  of
lesions,  but  rather  in  stabilization  of  progressive  disease.  The
RECIST guidelines recognize that progression free survival and/or
time  to progression may  be a  valuable  alternative end-point  to
provide an initial estimate of biologic effect for those agents.
Statistical  designs: The  classical  phase  II  designs  (Simon,
Fleming, Gehan) are only applicable to phase II trials with a binary
primary end-point (success vs failure). Success can be defined as
absence  of  objective  progression  (as  defined  by  the  RECIST
criteria) at a fixed selected time point (i.e. 3 or 6 months), if all
patients are followed until this point. This is a valid end-point only
if  disease  progression  has  been  documented  before  starting
therapy.
Target  success  rates: Two  baseline  parameters  are  needed  to
compute the sample size and decision rules with those designs: the
minimum success rates (i.e. progression free -PF- rate) expected
from an active drug (P1) and the maximum success rate expected
if the drug is inactive (P0). The success rate observed with the best
available regimen for the targeted patient population is generally
used as P1. We have estimated relevant PF rates for soft tissue
sarcoma trials from the STBSG database.
For non pre-treated patients, PF rates for active regimen were esti-
mated from the data of 1154 patients treated with 1st line anthra-
cycline  containing  chemotherapy,  with  an  externally  reviewed
diagnosis of leiomyosarcoma (531), mfh (217), synovial sarcoma
(115),  liposarcoma  (110),  fibrosarcoma  (68)  and  neurogenic
sarcoma (113). The 3 months estimated PF rates varied from 77%
(synovial sarcoma) to 58% (leiomyosarcoma) and the 6 months PF
rates from 56% (synovial sarcoma) to 38% (mfh). In 61 leiomyosa-
rcoma from GI origin (now identified as GIST), those figures were
44% and 30% respectively.
For pre-treated  patients,  PF rates  for active regimen  were esti-
mated from 124 patients treated with ifosfamide or DTIC, after
failure of anthracycline containing regimen. Overall PF rates at 3
and 6 months were estimated to be 44% and 18% respectively. PF
rates  for  inactive  regimen  were  estimated  from  253  patients
included in 2nd line trials with 9 agents that did not demonstrate
activity. In those patients, the overall PF rate at first disease evalu-
ation (6 to 8 weeks after treatment start) was 21%.
Conclusion: Progression  free rates  may be appropriate primary
end-points for phase Ii trials with non cytoreductive agents in soft
tissue sarcoma, but the patients’ selection, follow-up period and
parameters of the statistical design need to be adapted.
Evaluation  and  presentation  of  clinical  trial  data  on
sarcomas
I. JUDSON
(Royal Marsden Hospital, London, UK)
The  problem: Soft  tissue  sarcomas  (STS) are  a  heterogeneous
group of disparate diseases. Outcome is determined by disease site,
tumour size, grade and histological subtype. Nevertheless, owing
to their rarity, and the paucity of effective treatments, it remains160 EORTC Abstracts
common practice to conduct Phase II and Phase III trials of chem-
otherapy regimens in mixed populations of patients.
Trials of adjuvant chemotherapy provide an example of the diffi-
culty  caused  by  this  process.  Individually  these  have  generally
failed to demonstrate a survival benefit.1 In part this is due to their
small  size,  in  part  patient  heterogeneity.  The  meta-analysis
reported in 19972 aroused controversy owing to the inclusion of
studies  involving  patients  with  particularly  poor  prognosis,  e.g.
uterine sarcoma, and patients with indolent, low grade tumours,
and also the use of low dose regimens that would not conform to
current ideas of best practice. Overall the results showed a benefit
from treatment in terms of disease-free but not overall survival.
Nevertheless,  the  debate  served  to  highlight  the  results  of  the
Italian Sarcoma Group study reported by Frustaci  et al3 which
shows a survival advantage for aggressive chemotherapy in selected
patients  with  extremity  and  limb  girdle  high  grade  tumours.
Maturing data from this  small trial appear to confirm the  early
results.
How then are we to judge the results of studies carried out in mixed
populations of patients?
Assessing clinical trial data: Firstly, it is necessary to look care-
fully  at  all  the  known prognostic  factors.  Retrospective  studies
have been conducted using the  EORTC Soft Tissue  and Bone
Sarcoma  Group  database  of  over  2,000  patients  treated  for
advanced  or  metastatic  disease  with  anthracycline-containing
chemotherapy. These act as an excellent source of unbiased infor-
mation.  It  has been  demonstrated  that  favourable factors  for  a
response to chemotherapy are: absence of liver metastases, young
age, high grade and liposarcoma. Similarly, longer survival is asso-
ciated with: low grade, good performance status, long disease-free
interval from diagnosis, young age  and absence  of liver  metas-
tases.4 In a separate study it was shown that patients with small
metastases only in the lung are most likely to respond to chemo-
therapy.5 With regard to histological type, apart from the favour-
able response in the case of liposarcoma, the converse is clearly
true  for  visceral  tumours,  especially  gastrointestinal  stromal
tumours (GISTs) which rarely, if ever respond to cytotoxic chem-
otherapy.
In other words, if a Phase II study in advanced STS reports a 60%
response rate using a standard chemotherapy combination, it most
probably  means  that  the  investigators  have  selected  young,  fit
patients with extremity, high grade tumours, who have lung-only,
low volume metastatic disease. If the authors are unwise or unscru-
pulous they may wish to persuade us that their excellent results are
due to their special ‘recipe’, especially if dose escalation has been
used.  This  sort  of  bias  can  only  be  excluded  by  performing
randomised trials. For example an EORTC Phase II study used
GM-CSF to allow escalation of the dose of doxorubicin from 50 to
75 mg/m2 in combination with ifosfamide. An excellent response
rate  of  45%  was  obtained.6  Unfortunately,  in  a  subsequent
randomised trial there was no advantage for the higher  dose of
doxorubicin.7 Similarly, in a randomised Phase II trial comparing
standard doxorubicin  versus  liposomal  doxorubicin  (DOXIL®/
CAELYX®) both arms performed poorly with response rates of
only 9% and 10%.8 The latter response rate in a single arm study
would have resulted in the conclusion that CAELYX® was inac-
tive.  Increasingly,  our  improving  understanding  of  sarcoma
biology is resulting in the ability to treat individual tumour types
selectively.  The  demonstration  that  agonists  of  the  peroxisome
proliferator-associated receptor gamma (PPAR ) such as troglita-
zone, cause differentiation of certain types of liposarcoma offers
hope of improved therapy in this disease type.9 Recently, the intro-
duction of a receptor tyrosine kinase inhibitor for the treatment of
GISTs seems set to transform our ability to treat this otherwise
refractory disease. The introduction of such new treatments will
set the standard for defining the patient population under study,
since response will be determined by expression of the appropriate
receptor.
Presentation of trial data: In conclusion, in order for your data to
be meaningful to others, it is vital to include all the data you would
like  to  see  for yourself. All  prognostic information needs to  be
included. Any known bias  in patient selection  should be trans-
parent, and excessively optimistic claims should be avoided. Wher-
ever appropriate, molecular diagnostic techniques should be used
to clarify exactly what population of patients has been treated. The
precise methods used to assess treatment benefit need to given in
detail. In most cases promising results will require confirmation in
Phase III trials.
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Molecular  biology  and  cytogenetics  in  the  diagnosis  of
sarcomas
C.S.  COOPER,  J.  CLARK,  S.  EDWARDS,  P.  FLOHR,  M.
JOHN, I. GIDDINGS,  K. MAILLARD, R. WOOSTER & A.
JACKMAN
(Institute of  Cancer  Research, The  Haddow  Laboratories,  Cotswold
Road, Sutton, Surrey, UK)
With  the  publication of  the  human genome sequences and the
identification of around 40,000  human genes a major challenge
that now faces the scientific currently is how to use this information
to help cancer patients. One very powerful platform that can be
used to achieve this goal is microarray technology that allows many
thousands  of  genes  to  be  examined  simultaneously.  We  have
through the setting up of ICR ‘spotted microarray facility’ used this
technology in a number of distinct strategies.
CB30865  is  a drug  of  unknown mechanism  of  action  that  has
activity against a broad range of tumour cell lines. To investigate
the molecular basis of resistance to CB30865 we have used micro-
array technology to compare gene expression in a tymphoblatoid
cell line W1L2 with a variant of this line W1L2:R865 that shows a
300-fold increase in resistance CB30865. cDNA probes prepared
from the W1L2 cell line and from the W1L2:R865 cell line were
hybridized  simultaneously  to  a  microarray  of  7,000  clones
randomly  selected  from  a  cDNA  library  prepared  from  the
W1L2:R865  cell  line. These studies  led to the identification of
MSS1  which  encodes  a  component  of  the  26S  Proteosome
complex as a gene whose level of RNA expression correlated with
drug  resistance.  Based  on  these  observations  a  derivative  of
CB30865 called CB300919 was tested and subsequently discov-
ered to be an inhibited of cellular proteosome activity.
We have also used microarray technology to identify genes that are
amplified and overexpressed in human cancer. As a test system
initially  to  determine  that  the  procedure was working used  the
breast  cancer  cell  line  BT474  which  contains  amplicons  at
17q11–21 17q22–23 and 20q13. A microarray of 10,000 clones
randomly picked a cDNA library prepared from the BT474 cell
line was hybridised n comparative genomic hybridisation (CGH)
experiments  to  DNA  from  BT474  cells  and to  control  muscle
DNA. These studies identified 68 amplified genes from the three
chromosome 17 and chromosome 20 amplicons and studies on
gene expression were used to identify from these 5 new candidate
oncogenes. This procedure has now been applied to several ampli-
cons in human sarcomas and the results will be presented.EORTC Abstracts 161
Controversy  still  exists  over  the  correct  classification  of  some
groups of sarcomas. Particularly it has been proposed that malig-
nant fibrous histiocytoma may in most cases be reclassified pleo-
morphic leiomyosarcomas, rhabdomyosarcomas or liposarcomas.
We are currently using microarray technology to collect expression
profiles of primary sarcomas and using hierarchical clustering to
determine the relation of MFH tumour to other tumour groups.
Preliminary  results  of  these  analyses  will  be  presented.  We
conclude that microarray technology represents a powerful tech-
nique that may be utilised in several distal approaches to aid in the
management  of  human  sarcomas.  (We  acknowledge  the  Cancer
Research Campaign for their support of this project)
Any role left for sarcoma pathology?
C.D.M. FLETCHER
(Brigham & Women’s Hospital & Harvard Medical School, Boston,
USA)
The title chosen for this talk by the organisers is, of course, provoc-
ative and deliberately naïve. There is no question that cytogenetics
and molecular genetics have had significant impact on our under-
standing of mesenchymal neoplasia and, in certain circumstances,
on our ability to make objective and more reproducible diagnoses.
There  is  also  some  limited  evidence  to  suggest  that  molecular
genetic data may provide prognostic information in certain tumour
types. The role of gene expression profiling is, as yet, largely unex-
plored  but  to  date  has  only  validated  conventional  pathologic
subclassification in other types of cancer. However, the notion that
these techniques will supplant conventional histopathological anal-
ysis within the coming 20–25 years is essentially laughable for the
following four major reasons:
1. In simple numerical terms, the majority of soft tissue sarcomas
do not show any specific, consistent or currently detectable
cytogenetic or molecular genetic abnormality;
2. In light of their morphologic heterogeneity, a substantial pro-
portion of soft tissue sarcomas can only be recognised as such
by  conventional  histopathology—there  are  no  surrogate
molecular genetic markers of malignancy;
3. The  technologies  required  to  take  optimal  advantage  of
molecular  genetic/cytogenetic  analysis  are  available  in  very
few centres and are often poorly integrated with clinical need;
4. Cost constraints, the need for appropriately trained staff and
the relative rarity of soft tissue sarcomas combine to make it
very improbable that most institutions will establish and utilize
molecular genetic techniques in the foreseeable future.
The fact remains that conventional pathologic analysis, in partic-
ular accurate histologic  subtyping and (in  some  circumstances)
grading, provides the most crucial information in terms of diag-
nosis,  prognosis  and  determination  of  therapy  in  soft  tissue
sarcoma patients. Furthermore, the wide availability of this diag-
nostic methodology, its exceptional cost effectiveness and the rela-
tive ease with which tissue samples (or slides) can be shared with
other pathologists (or treatment centres) make it highly unlikely
that this approach will be superceded in our lifetimes.
Having said that, molecular genetic approaches will unquestion-
ably bring new information and insights which in, in combination
with  the  constant  advances  in  clinicopathologic  assessment  of
these tumours, will help to refine diagnosis, classification and prog-
nosis, at least in some major academic centres. The two main goals
in the coming decades should be a) to facilitate a collaborative/
integrated  approach between  clinical  and  more  basic  scientists
working on soft tissue sarcomas in pathology/oncology and b) to
ensure that as many patients as possible are treated in specialist
centres, in which best advantage can be taken of any diagnostic and
prognostic advances.
The  impact  of  molecular genetics  on the  future manage-
ment of sarcomas
L. HELMAN
(National Cancer Institute, Bethesda, Maryland, USA)
The increasing application of molecular techniques in sarcomas is
having significant impact on our ability to diagnose, make prog-
nostic predictions and treat a variety of sarcomas. The discovery
of recurrent reciprocal translocations in a variety of sarcomas and
the subsequent cloning of the resultant fusion genes have fueled a
major change in the diagnostic criteria for such tumors. The ease
and widespread application of RT-PCR enables pathologists  to
confirm  or  question  diagnoses  based  on  molecular  criteria.
Furthermore, translocation-derived fusion proteins have recently
become the target of immunotherapy approaches. Specific techno-
logical  advances  are  also  beginning  to  profoundly  affect  the
management  of  sarcomas.  The  increasing  ease  of  sequencing
tumor DNA has led to the identification of specific point muta-
tions in genes leading to alter signaling of the tumor cells. This
finding, in turn, has led to a widespread effort to develop drugs
specifically targeting the! se altered signaling pathways. A recent
example of the success of this approach is the use of STI 571 in
treating  GIST  tumors,  where  the  drug  specifically  targets  the
alteration in the c-Kit gene seen in these tumors. More recently,
the  application  of  expression  profiling  or  array  technology  to
sarcomas has the potential to further refine the classification of
these tumors and identify new potential therapeutic targets. We
are just beginning to see the potential power of high-throughput
SNP technology to identify risk categories and critical signaling
pathways in these tumors. Illustrations of these approaches and
their  effects  on  clinical  management  of  specific  tumors  will  be
discussed.
Medical imaging of soft tissue sarcomas
A.M.A.  DE  SCHEPPER,  L.H.L.  DE  BEUCKELEER,  X.
WANG & J. GIELEN
(University Hospital Antwerp, Belgium)
We  will  present  the  ability  of  magnetic  resonance  imaging  in
staging, grading, tissue characterization, percutaneous biopsy, and
post therapeutic surveillance of soft tissue tumours. Well known
staging parameters such as extent, relationship with adjacent struc-
tures, and detection of intralesional necrosis are used in the MR
protocol for locoregional staging. Bone scintigraphy and high reso-
lution CT scan of the lungs are best methods for ruling out meta-
static  spread. A variety of (solitary or combinations of) grading
parameters is described in radiological literature. The role of MR
imaging is to afford recognition of these lesions that need further
aggressive  work-up,  excluding  all  others.  Despite  controversial
reports, the definite role of MR imaging in grading of soft tissue
tumours seems to become established. As for grading, a lot of indi-
vidual parameters used for tissue characterization have low sensi-
tivity,  but  combinations  of  these  parameters  (age,  site,  signal
intensities, …) are more useful and often allow to predict a specific
diagnosis or to narrow down the list of differential diagnosis. Local
recurrences of soft tissue tumours are frequent and can be detected
accurately by an ‘easy-to-use’ MR algorithm. A comparative study
between MRI and ‘whole specimen’ histopathology proves that the
MR signal of different tumour components can easily be explained
by their different histological composition but that the creation of
MR prototypes of various soft tissue tumours is illusory because of
tumour  components  may  be  intermingled,  change  in  time  and
sometimes have adverse effects on the overall MR signal intensity.
Moreover cellularity, extent of extracellular spaces and relation-
ship between nuclear and cytoplasmatic size will influence signal
intensity  on  different  pulse  sequences.  The  value  and  risks  of
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Future role of PET in diagnostics and response evaluation of
sarcomas?
S. STROOBANTS
(Department of Nuclear Medicine, U.Z. Gasthuisberg,  KU Leuven,
Leuven)
Over  the  last  years,  positron  emission  tomography  (PET)  has
gained  widespread  enthusiasm  as  an  innovative  technique  in
oncology. In contrast to conventional imaging techniques, such as
computed tomography (CT), ultrasound (US), and magnetic reso-
nance imaging (MRI), which are based on differences in density of
tissues, PET relies on the differences in metabolism of cancer cells.
For instance, most tumour cells have a higher rate of glycolysis in
comparison with non-neoplastic cells. This change in carbohydrate
metabolism  can  be  visualized  with  PET  using  the  radioactive
glucose analogue called fluorodeoxyglucose (FDG). PET has the
possibility  of imaging the whole body within one image session
(frequently used in staging procedures) and is able the quantify
changes  in  metabolism,  a  parameter  of  use  in  evaluating  the
aggressiveness of the tumour or assessing response to treatment.
Although the experience of PET in oncology is growing fast, data
on the value of PET in the management of sarcomas is limited and
mainly focusing on the ability  of FDG-PET  in differentiating
benign  from  malignant  (mostly  soft  tissue)  masses.  FDG
uptake  in  high-grade  sarcoma  proved to be significantly  higher
than those of benign or low-grade tumours, although there was a
substantial overlap between the groups. Also the pattern of FDG
within the mass seemed related to the histopathologic grade:
very heterogeneous in high-grade and uniform or absent in the
low-grade ones. Further insight in the association between FDG
uptake and other pathologic features was given by Folpe et al.1 who
found that FDG uptake was associated not only with histopatho-
logical grade but also with cellularity, mitotic activity, MIB labe-
ling index, and p53 overexpression. Since clinical management is
depending on histopathologic grading and sarcomas are heteroge-
neous neoplasms, FDG-PET may help ensure accurate grading by
guiding biopsy toward the most biologically significant regions of
large  masses.  Further  follow-up will  be  necessary  to determine
whether FDG-PET provides independent prognostic information.
Data on the value of FDG-PET in detection of disease extend
is  limited.  Lucas  et  al.2  evaluated the  capacity  to identify  local
recurrence  (compared  to  MRI)  and  pulmonary  metastases
(compared to CT) in 62 patients with soft-tissue  tumours after
treatment. For the detection of local disease, MRI proved to be
more accurate than  PET whereas for the  identification  of lung
metastases, CT proved to be the most sensitive and PET the most
specific technique. The major advantage of PET was its ability to
detect other metastases at unexpected sites.
Finally, PET can be used to evaluate the effect of treatment.
Since metabolic  changes precede the  morphological ones, PET
seems  a  promising  tool  to  discriminate  responders  from  non-
responders,  more  accurate  and  much  earlier  than  anatomical
imaging. Schulte et al.3 evaluated the use of PET in estimating the
grade of tumour regression after neoadjuvant chemotherapy in 27
patients with osteosarcoma prior to surgery. The decrease of FDG
uptake  showed  a  close  correlation  to  the  amount  of  tumour
necrosis induced by chemotherapy. With a cut-off level of 0.6, all
responders and 8 of 10 non-responders could be identified. In an
ongoing study in our own hospital in patients with GIST tumours
treated with the experimental drug STI 571, a very rapid decline in
FDG uptake (as soon as 48hours after the initiation of therapy)
was observed in 12/22 patients, often corresponding with symptom
relief. In the 6 patients with an early increase in FDG uptake, a
rapid deterioration of clinical symptoms was seen. While there was
a clear discrimination between responders and non-responders on
PET, no major change in tumour volume was observed on CT.
With the introduction of new, often non-cytotoxic drugs, no major
changes in tumour volume is to be expected and therefor therapy
evaluation based on metabolic changes will be become more and
more important.
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Local staging of musculoskeletal sarcomas-how good are we?
A. SAIFUDDIN
(The Royal Orthopaedic Hospital, Stanmore, Middlesex, United King-
dom)
Local staging is vital in the planning of surgery for bone and soft-
tissue sarcomas. The majority of published work on musculoskeletal
tumour staging has dealt with osteosarcoma since this is by far the
commonest primary malignant bone tumour. This paper reviews the
literature on the  local staging  of high-grade central appendicular
osteosarcoma. It is assumed that the findings can be extrapolated to
other bone sarcomas. Imaging techniques available include radiog-
raphy, scintigraphy, CT and MRI. MRI is currently the technique
of choice. The factors that need to be addressed are; 1) intramedul-
lary tumour extent, including identification of ‘skip’ metastases and
relationship of tumour to the growth plate and epiphysis, 2) relation-
ship of tumour to the adjacent joint and 3) relationship to the adja-
cent  major  neurovascular  structures.  Tumour  volume  is  also
important in terms of prognosis, particularly for Ewing’s sarcoma.
1) Intramedullary tumour extent: several studies have assessed the
accuracy  of  MRI  by  comparing  imaging  with  pathological
macroslides.  It  has been shown that  an unenhanced coronal or
sagittal  T1  weighted  spin  echo  sequence  is  highly  accurate  in
assessing intramedullary tumour extent. Both STIR and contrast
enhanced T1 weighted fat saturated sequences tend to overesti-
mate  intraosseous  tumour  since  they  are  sensitive  to  adjacent
marrow  hyperaemia  and oedema.  MRI  can  also  identify  ‘skip’
metastases, and in this respect is more sensitive than radiography
and bone scintigraphy. MR imaging of the whole bone is an abso-
lute  requirement.  However, no  study  has  been  performed  that
looks at the sensitivity and specificity of MRI in the evaluation of
‘skip’ lesions. Personal experience indicates that not all additional
intramedullary  lesions  identified  at  imaging  represent  ‘skip’
lesions. Pathological studies have shown that involvement of the
growth plate and epiphysis by metaphyseal osteosarcoma occurs in
up to 80% of cases. This can be accurately assessed by MRI. Again,
an unenhanced T1 weighted sequence is most  accurate. Direct
evidence of tumour extension is  the  most  reliable  finding.  The
presence of only oedema in the epiphysis is not a specific finding.
2) Relationship of tumour to the adjacent joint: intra-articular exten-
sion is most commonly a feature of distal femoral osteosarcoma,
and typically  occurs in the  intercondylar notch at the proximal
insertion of the anterior cruciate ligament. A pathological fracture
into the joint also signifies joint contamination. Both are clearly
identified  by  MRI.  However,  the  important  differentiation
between intra-capsular/extrasynovial and intra-capsular/intrasyno-
vial extension has not been assessed. The presence of a joint effu-
sion is a common and non-specific finding.
3) Relationship of tumour to the adjacent neurovascular structures: this
determines the feasibility of limb-salvage surgery and is best assessed
using  an  axial  T2  weighted  MR  sequence.  Involvement  of  the
neurovascular structures by extraosseous tumour may be graded on
MRI as definitely  absent, equivocal  or definitely  present. In  the
former and latter cases, MRI correlates accurately with surgical find-
ings. When MRI appearances are equivocal, a safe surgical plane can
be achieved in 40–70% of cases. Dynamic enhanced MRI studies
can differentiate extraosseous tumour from perineoplastic oedema
but the clinical relevance of this needs clarification.EORTC Abstracts 163
STS—Which  surgical  questions  need  to  be  answered  in
future studies?
R.J. GRIMER
(Royal Orthopaedic Hospital Oncology Service, Birmingham, UK)
Surgical aspects of the treatment of STS have largely been ignored in
studies of the treatment of STS. Surgical excision of the tumour is
however still the largest single intervention that most patients with
STS will undergo and thus ‘getting it right’ is essential. There are
many reasons for this including the  variety of surgeons who treat
them, the large number of centres where they are treated and the near
impossibility of doing a randomised controlled trial in any surgical
field. However, there are still many surgical questions to be answered
and we need to think of ways to approach these. Some of these are:
1. Does it matter who operates on STS?
2. Is there a critical number of sarcomas one should operate on
per year to be ‘safe’?
3. Is a biopsy essential for retroperitoneal STS?
4. How wide does a wide margin need to be?
5. Is local control important to maximise overall survival?
6. Are there tumours where amputation is the safest option?
7. Is a planned marginal excision safer than an unplanned one?
8. When do you peel vessels of the tumour and when do you
reconstruct them?
9. Are two operations better than one?
10. What  are  the  cost  /  benefit  ratios  of  early  plastic  surgical
reconstruction in ‘at risk’ sites  eg. large adductor compart-
ment tumours?
11. How do you prevent seromas—does it matter?
These are just some of the questions which surgeons ask them-
selves and their colleagues from time to time. These questions have
been circulated in advance of the meeting to an interested group of
STS surgeons—their  responses  have been analyzed and will  be
discussed in an attempt to define what questions really do need
answering and how we might go about this.
Which  questions  in  radiotherapy  need  to  be  answered  in
future studies?
B. O’SULLIVAN
(Princess Margaret Hospital, Toronto, Canada)
Introduction: The use of adjuvant radiotherapy (RT) has greatly
expanded the opportunities for conservative surgery in soft tissue
sarcoma (STS). Although ample evidence of efficacy exists, the
best way to use RT (or sometimes its indications) remains unclear.
This presentation will focus on STS and will address a number of
continued controversies while recognizing that current strategies
provide high rates of local control in many sites.
Omission  of  RT: Undoubtedly  a  favorable  population  exists
where  RT  is  unnecessary  with  appropriate  surgery  (e.g.  well
contained lesions) but the limits of this approach are uncertain. In
contrast, there are unfavourable groups where radiotherapy may
also not be useful, and the prognosis is universally poor, e.g. retro-
peritoneal sarcoma (RPS). Certainly in RPS a randomized trial
addressing this  issue  would be valuable since  patients are often
destined to die with present approaches, which are both potentially
toxic as well as inadequate. In the more favorable lesions criteria
for  selection  are  needed  and  should  be  applied  and  studied
prospectively to determine selection for surgery alone.
Reducing Toxicity of RT: The prospective trials have yielded infor-
mation but questions remain. In the Canadian SR2 trial, total dose
and increased volume was associated with long term limb fibrosis.
Strategies to reduce the total dose of radiotherapy delivered, or the
biologic  dose  through  exploitation  of  optimal  fractionation
approaches have not been addressed prospectively. In the future, it
may  also  be  possible  to  prospectively  evaluate  radioprotective
agents, or replacement of damaged tissue at the macroscopic or
cellular level. Opportunities to protect tissues by exclusion from
the target volume should be exploited and studied. This is espe-
cially important where tissues are critical and dose limiting. The
potential to treat RPS with untethered bowel displaced by an unre-
sected tumor offers potential gain with preoperative RT. In this
scenario, there is minimal contamination of the abdominal cavity,
the  tumor vascularity is  intact, and the  fields  are smaller.  This
approach could readily be the focus of a trial supported by those
who are discouraged by the value of post-operative  RT in RPS
where RT administration is difficult to administer.
Assessment of Toxicity: The SR2 trial also revealed that volume
irradiated is strongly associated with poor function and limb edema.
Yet  we  are  unaware  whether  this  relates  to  total  proportional
volume of the limb treated or to proportion of the cross-section of
the limb irradiated. In order to address such issues prospective valid
and reliable measures of toxicity must continue to be developed and
accurate documentation of treatment implemented.
Definition of Target Volumes: Because volume is important there
is an urgent need to define the volume at risk. Clinico-pathologic
studies are needed for radiotherapy planning to permit reduction
in  normal  tissues  irradiated.  The  significance  of  peritumoral
edema on MRI is unknown. This and other imaging knowledge
(e.g. PET) must be evaluated to permit optimum surgical and radi-
otherapy target delineation.
Optimum Volume and Combined Modality Approaches: Knowledge of
optimum volume will provide the opportunity to combine concurrent
chemotherapy  with  radiotherapy and spare  morbidity  by  treating
smaller  volumes  with  conformal  plans,  high-resolution  intensity
modulated radiotherapy (IMRT), or brachytherapy. The compara-
tive  benefits  of  these  and  other  approaches  (e.g. limb  perfusion)
requires study from the context of cost, wound healing, function,
combined chemoradiotherapy toxicity and, of course, local control.
Summary: The evaluations described provide much opportunity
for future research in the use of RT in STS and will be discussed
with examples.
Isolated limb perfusion with TNF for locally advanced soft
tissues sarcomas: any role outside dedicated centres?
FERDY J. LEJEUNE
(Centre Pluridisciplinaire d’Oncologie, CHUV, Lausanne, Switzerland)
Background and introduction: Some sixty percent of Soft Tissue
Sarcomas (STS) occur in the limbs  Amputation used to be the
standard treatment for these extremity lesions but it has now been
replaced by limb-sparing surgery in about 90% of patients, without
significant impairment of limb function. In the remaining 10% the
tumour involves the neurovascular bundle, is very large, is close to
an articulation or consists of multiple nodules. In these settings,
treatment remains primary amputation and radiotherapy is ineffec-
tive. Sadly, however, amputation does not improve life expectancy,
because distant micrometastases, mainly pulmonary have usually
already grown. We  reported that  Isolated  Limb  Perfusion with
TNF/IFN gamma and melphalan (TIM-ILP) is an efficient treat-
ment  of  inoperable  soft  tissue  sarcomas  and melanoma  of  the
extremities (1). Moreover, this treatment is a limb-sparing  neo-
adjuvant therapy when it is  followed by removal of the tumour
remnant(s) (2).
Method: The  rationale  is  that  isolated  perfusion  allows  high
regional concentration of drugs, respectively TNF which targets
tumour  associated  vessels,  and  melphalan,  an  alkylating  agent,
which targets tumour cells (3).
The technique  is  sophisticated  and requires  a  multidisciplinary
team of surgeons with know how in extremity surgical oncology
and isolated limb perfusion procedure, anaesthesiologists special-
ised in intensive care, nuclear medicine specialist for continuous
monitoring of leakage to the general circulation, and pump tech-
nicians  familiarised  with  hyperthermic  isolated  limb  perfusion.
The procedure includes the surgical isolation of the limb major
vessels and their connection to the extracorporeal circuit, under
tourniquet. For TM-ILP, high dose TNF (3 mg upper or 4 mg
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detected and when tissue temperature reaches 38ºC. In the past,
for  TIM-ILP  0.2  mg  IFN  gamma  was  added.  High  dose
melphalan is administered 30 min later, when vascular permea-
bility  has been increased by TNF. Perfusion ends after 90 min
and the limb vessels are intensively washed of residual drugs. The
whole  procedure  takes  around  5  hours.  For  safety  reason,  the
patient is admitted in intensive care unit for at least half a day.
Results: The European TNF/ILP Assessment  Group evaluated
260 patients with irresectable STS enrolled in 10 years into four
studies with similar protocols to determine whether TM (TNF/
melaphalan) or TIM (TNF/IFN gamma/melaphalan)-ILP offers
durable limb salvage by effective local control of the tumour with
or without subsequent surgery (4, 5). Patients were reviewed by an
Independent Review Committee and compared with convention-
ally treated patients (often by amputation) of a population-based
Scandinavian STS Database, since randomised studies were never
considered in view of the high response rate and high limb sparing
obtained after TM or TIM-ILP.
The proportion of patients who had achieved durable limb salvage
ranged from 74% to 87% in the  four studies and the  objective
(complete  plus  partial)  response  rates  were  56.5–82.6%.  The
Independent  Review  Committee  considered  that  80%  of  all
enrolled patients met the criteria for irresectability. As proven by
matched-pair  comparison,  the  ILP  treated  patients  survived  as
long as conventionally treated patients from the Scandinavian STS
Database.
In Lausanne, we reviewed our results as a single centre performing
TIM or TM-ILP as a limb  salvage  treatment  for initially  non-
resectable soft tissue sarcomas of the extremities (6).
Twenty-two patients (6 men and 16 women; 3 upper limb and 19
lower  limb  tumours)  were  enrolled.  AJCC  stage  was  IIA  in  4
patients, III in 7 and IV in 11. Thirteen cases were recurrences or
progressions after previous therapy; 5 tumours had a diameter   20
cm, and 4 were multiple  or regionally metastatic. There were 6
malignant  fibrous  histiocytomas,  5  liposarcomas,  4  malignant
schwannomas (malignant peripheral nerve sheet tumours), 3 rhab-
domyosarcomas, 2 leiomyosarcomas, 1  recurrent extrasquelettal
osteosarcoma and 1 angiosarcoma.
Twenty-four ILPs were performed in the 22 patients; 18 (82%)
experienced an objective response: it was complete in 4 (18%) and
partial in 14 (64%). Three patients had minimal or no response
and the tumour progressed in one case. All patients had fever for
24 hours but only one developed a grade 3 reversible distributive
shock syndrome with no sequellae. There was no grade 4 toxicity.
Seventeen patients (77%) underwent limb sparing resection of the
tumour remnants after a median time of 3.4 months: 10 resections
were  intracompartmental  and  7  extracompartmental.  Surgery
included flaps or skin grafts in 5 patients, arterial replacement in 2
and knee arthrodesis in 1. Adjuvant chemotherapy was given to 8
patients and radiotherapy to 6. One patient had to be amputated
after second ILP.
Secondary  amputations  were  performed  for  recurrence  in  two
patients, resulting in an overall limb salvage of 19/22 (86%).
After  a  median  follow  up  of  28  months,  10  recurrences  were
recorded: 7 were both local and systemic and 3 were only local.
The median disease free and overall survival have been > 12.5 and
18.7  months  respectively:  this  is  similar  to  the  outcome  after
primary amputation for similar cases.
Conclusion: We conclude that ILP with TNF and chemotherapy
is an efficient limb sparing neoadjuvant therapy for a priori non-
resectable limb soft tissue sarcomas, a condition that only repre-
sents 10% of limb STS. The procedure is sophisticated and costly,
it requires continuous experience of a multidisciplinary team. For
performing at least one ILP per month, only one centre is needed
for a 5 million population basin. We recommend the implementa-
tion of an European Quality Assurance Programme.
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Prospective  role  of  chemotherapy  combined  with  hyper-
thermia in sarcomas?
ROLF D. ISSELS1,2 & CLEMENS-M. WENDTNER1
(1University Hospital Medical Clinic Grosshadern, Medical Clinic III,
D-81377 Munich and 2KKG Hyperthermie, GSF-National Research
Center for Environment and Health, D-81377 Munich, Germany)
Purpose: To evaluate the efficacy of neoadjuvant chemotherapy
combined  with  regional  hyperthermia  (RHT)  in  adult  patients
with non-metastatic high-risk soft tissue sarcomas (HR-STS). We
report upon the results of two consecutive phase II studies and
present a subgroup analysis for patients with retroperitoneal and
visceral HR-STS.
Patients: 113 patients with HR-STS (non-resectable primary/S1,
recurrent/S2, inadequately resected/S3) located within extremities,
trunk  or  abdomen were  treated  within  a  neoadjuvant phase  II
protocol (RHT-91 or RHT-95). HR-criteria were: tumor grade II/
III + tumor size (>8cm for RHT-91; >5cm for RHT-95) + extra-
compartmental  extension.  The  RHT-91  protocol  (59  pts)
included 4 cycles of preoperative chemotherapy (XT) plus RHT,
followed by surgery and 4 cycles of adjuvant XT plus RHT. In
addition,  R1/R2-resected  pts  received  radiation.  The  RHT-95
protocol  (54  pts)  was  identical  except  that  pts  after  surgery
obtained XT without RHT and adequate radiation regardless of
resection  status.  XT  of  both  studies  consisted  of  etoposide
(125mg/m2) on day 1+4, ifosfamide (1500mg/m2) on day 1 to 4,
and adriamycin (50mg/m2) on day 1 (EIA). RHT (1hr at 42.5ºC)
was given on day 1+4.
Results: Radiographic response in 52 evaluable pts of the RHT-
91 (42%) and in 32 assessable pts of the RHT-95 study (28%)
included 1+0 CR, 8+5 PR, 13+4 MR, 17+10 SD and 13+13 PD,
respectively. Among 74 pts undergoing surgery, amputation rate
was <15%. After  different median observation times  (RHT-91:
58mo/  RHT-95:  30mo)  probability  of  overall  survival  (42%  vs
48%;  p = 0.392)  and distant progression free survival (51%  vs
64%; p = 0.357) are quite similar for both studies. Subgroup anal-
ysis (S3 vs S1, S2) for overall survival revealed also no significant
difference (47% vs 48%; p = 0.616). Interestingly, local relapse
free survival was in favour of the RHT-91 study, which included
pre- and postoperative RHT (58% vs 57%; p = 0.021).
Among these patients, we performed also a subgroup analysis for
58 HR-STS with retroperitoneal or visceral (RP/V) STS. Radio-
graphic  response  after  neoadjuvant  thermochemotherapy  was
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rate of 33%. After completion of protocol treatment, 25 patients
(43%) had no evidence of disease (NED). 5-year probabilities of
only  local  failure-free,  any local  failure-free,  distant  metastasis-
free, event-free and overall survival (OS) were 53%, 25%, 51%,
20% and 32%, respectively. Median OS was 31 months for the
entire study cohort, while OS was in favor of patients with NED
vs. NON-NED status  (76  vs. 20  months; P = .0001).  Patients
responding to neoadjuvant thermochemotherapy associated signif-
icantly with NED (P = .008). At 5-year follow-up, probability of
OS was in favor of patients responding to neoadjuvant thermoche-
motherapy (60% vs. 10%; P = .0014).
Conclusions: Based  on  these  results,  a  randomized prospective
phase III intergroup study (EORTC 62961/ESHO RHT-95) with
transatlantic participation is ongoing comparing EIA +/- RHT in
previously defined (S1-S3) risk groups and includes pre- and post-
operative RHT in the experimental treatment arm. Since July 1997
more than 100 pts have been randomized and treatment within this
protocol is feasible and safe while impact on local disease control
and survival has to be awaited.
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Why  have  these  new  local  treatments  not  become  more
widespread? General discussion
M.H. ROBINSON
(Cancer Research Centre, Weston Park Hospital, Sheffield, UK)
There  have  been  up  to  80  reports  of  the  use  of  isolated  limb
perfusion in the treatment of extremity soft tissue sarcoma since its
introduction in 1985. It is a technique whose use is almost entirely
confined to parts of Europe and which has not gained widespread
acceptance.  However,  the  multitude  of  published  studies  have
clearly  indicated  that  perfusion  techniques  are  capable  of
producing complete remission rates  of up to 30% with 80%  of
limbs being spared amputation. These remission rates cannot be
achieved by other more widely used techniques such as pre-opera-
tive  radiotherapy  with  or  without  chemotherapy.  The  issue  is
therefore why hasn’t ILP gained wider acceptance? The answers
revolve around the indications, results, complications and alterna-
tives for these novel techniques.
The first issue is patient selection. One surgeon’s selection criteria
for amputation may be different to another. In a busy sarcoma unit
only 5% of patients may require an amputation as treatment for
their extremity sarcoma. This means that only a small proportion
of referred patients are suitable for experimental local techniques.
Other  options are less  technically  demanding e.g. pre-operative
chemo-radiotherapy.  The  superiority  of  HILP  over  these  tech-
niques has never been convincingly proven. ILP is a complex tech-
nique, which has a considerable potential for side effects, which
requires considerable surgical experience for its safe delivery. TNF
alpha is severely toxic if it escapes into the systemic circulation.
There is debate in the literature around the other potential side
effects.  Klicks  (1998)1 found only 10  vascular complications in
466 ILPs (2.1%), all occurring in women. Drory (1998)2 reported
minimal clinical signs of peripheral nerve damage in 7/10 patients
undergoing  HILP.  This  was  mild,  didn’t  disturb  function  and
improved over time. The safety of radiotherapy with HILP is also
debated. Vrouenraets (1997)3 reported considerable risk of tissue
necrosis  and  impaired  healing  when  they  were  used  together.
Olieman (1998)4 found no difference in morbidity.
How do practitioners of novel techniques such as HILP and other
hyperthermic procedures convince the rest of us that investment in
the time and money required to safely deliver them is worthwhile?
Not easily is the  answer. One more difficulty  in the  way is the
uncertain connection between local control and improvements in
survival. Patients selected for these procedures usually have a very
high risk (>50%) of developing fatal metastases even where local
control  is  achieved.  A  recent  European  Consensus  meeting
suggested that proponents of these techniques should carry out a
prospective study in which the patients are selected for treatment
by  an independent panel of  experts.  The  alternative  is  a  rand-
omized trial, which seems impractical. A detailed study of conse-
quent limb function would be essential as treatment is palliative in
a significant proportion.
The evaluation of new techniques is a challenge to modern money
conscious health care systems. In Britain new treatments (espe-
cially  drugs)  are  subjected  to  thorough  examination  by  the
National Institute of Clinical Excellence before being made avail-
able  on  the  NHS.  Such  a  review  of the  value  of  HILP  would
undoubtedly return a verdict of ‘not proven’.
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Adjuvant  chemotherapy  has  no  effect  on  survival—the
EORTC experience.
V.H.C. BRAMWELL
(London  Regional  Cancer  Centre,  790  Commissioners  Road,  East,
London, Ontario, Canada N6A 4L6)
Purpose: In the past 25 yrs, the EORTC STBSG has conducted
3 randomized trials (RCT) evaluating the role of adjuvant chemo-
therapy  in  adult  patients  with  soft  tissue  sarcomas  (STS).
Presented here are updated results for trial 62771 (Bramwell et al.
J Clin Oncol 12:1137, 1994), and a recent analysis of trial 62874
(Gortzak et al. Eur J Cancer, 37:1096–1103, 2001). Trial 62931 is
in progress.
Trial #/dates Patients entered Eligible Patient characteristics Chemotherapy (CT)*
62771 468 317 age 15–70 CYVADIC × 8
1977–1988 all sites, grades post-surgery
62874 150 134 age 15–75 DOX (50 mg/m2)
1988–1995 high risk (grade II, III or size >8cm IFOS (5g/m2)
or recurrent/residual) all sites neoadjuvant
62931 ongoing age 16–70 DOX (75 mg/m2)
1995– target accrual 340 grade II, III all sites + IFOS (5 g/m2)
+ G-CSF post-surgery
*All patients receive optimal local treatment (complete resection ± radiotherapy) and are randomized between control and chemotherapy
arms DOX = Doxorubicin; IFOS = Ifosfamide; CYVADIC = Cyclophosphamide//vincristine/DOX/Dacarbazine166 EORTC Abstracts
Patients  &  methods: Trial  accrual  and design  are  summarized
below:
Results: For trial 62771,  there is no significant difference (p =
0.84) in overall survival (OS), despite significant reductions (p =
0.008 and 0.006 respectively) in local recurrence (LR) and relapse
free survival (RFS) favoring CYVADIC. A reduction in LR is only
apparent  in  the  group of head, neck  and trunk sarcomas  (p =
0.002) but not in limb sarcomas (p = 0.31).
For trial 62874, there also are no significant differences in RFS (p
= 0.35) and OS (p = 0.22), nor in the incidence of LR.
Discussion: Despite trial 62771 being the largest RCT to date of
adjutant CT in STS, it was not possible to demonstrate a significant
improvement in OS for CT, a result reflected in the SMAC meta-
analysis (Lancet 350:1647, 1997) to which it contributed  30% of
patients. Strengths and limitations of this study will be critically
reviewed. However, reduced LR rates were felt to indicate a positive
effect of CT and this was explored further in trial 62874. Designed
as a phase II feasibility study of neoadjuvant CT, this latter trial was
underpowered to detect a significant difference in 5 yr OS. Toxicity
was tolerable  and chemotherapy did not interfere  with planned
surgery, nor affect postoperative wound healing. However, slow
accrual  highlighted  difficulties  in  recruitment  to  a  multicentre
neoadjuvant protocol. Although inter-trial comparisons are subject
to bias, in trial 62874 the lower rate of local recurrence in high risk
STS is encouraging, and perhaps reflects advances in local manage-
ment. Dose intensification of DOX in trial 62931 remains a relevant
question, but accrual to this study is slow.
Italian experience on adjuvant chemotherapy of adult soft
tissue sarcomas.
S.  FRUSTACI*,  A.  DE  PAOLI*,  A.  BUONADONNA*  &  P.
PICCIº.
(Italian Sarcoma Group (ISG). *C.R.O., Aviano, ºRizzoli, Bologna;
Italy)
The role of CT in STS represents a matter of debate. No conclu-
sive data have been obtained from the concluded trials. However,
some points deserve discussion. FIRST GENERATION TRIALS:
From 1973 to 1990, 14 randomized trials have been conducted.
The  intrinsic  bias  was:  broad selection  criteria;  use  of  inactive
agents (VCR, CTX), low doses of the actives ones; low number of
accrued  patients.  META-ANALYSIS:  The  first,  performed  on
individual  patients  records,  revealed  an  impact  on  local-DFS,
distant-DFS  but  only  a  trend  for  the  OS.  In  the  subgroup  of
extremities including 886 pts, also the OS was statistically different
between CT and control (FU)(p = 0.029). SECOND GENERA-
TION TRIALS: In the early ’90s, further prospective randomized
trials were designed worldwide and in some instances activated by
different groups. Their main differences were: restricted selection
criteria  (high  risk),  use  of  antracyclines  and  ifosfamide  only,
hematopoietic growth factors and the limited  number of cycles.
The differences are: dose-intensity, time of starting chemotherapy.
RESULTS OF THE ISG TRIAL:
—intention to treat-analysis: From 6/92 to 11/96,  104 pts were
assigned to CT or FU. The interim analysis was presented(ASCO
’97;  Abs.Noc *1785)  and the  further yearly  analyses  were  also
reported(ASCO’99;ABS.Noc*2108).  The  mature  results,
obtained after a median follow-up of 59 months still confirm the
advantage  of  the  chemotherapy  group  in  comparison  with  the
control group in terms of survival and overall disease free survival.
The major advantage is however obtained in delaying the relapse
either locally or at the lung level, whereas the amount of distant
events is similar in both arms (JCO, vol. 19(5);2001).
—subgroups  analysis: Beside  the  intention  to  treat  analysis,
further aspects have been looked at: Efficacy of chemotherapy (effi-
cacy), exclusion from the analysis of those patients never starting
chemotherapy (7 patients in the treatment group); Impact of the
dose intensity (D.I.), comparison of those pts receiving a D.I.  85%
versus <85% and versus the control group; Evaluation of the post-
relapse  survival  (Post-rel-Surv),  comparison  of  the  survival  of
treated and untreated groups after the relapse. Preliminary data: the
analysis of the three above mentioned aspects also seem to indicate
the usefulness of adequate chemotherapy in the adjuvant setting in
a high risk patient population.
Conclusions: The present Italian trial, with an adequate follow-up,
strongly indicates the activity of adjuvant chemotherapy in a high-
risk patient population. This efficacy and gain in survival is however
mainly due to a delay in relapse either local or at distant sites rather
than a real decrease in distant events. However, this substantial
delay is worthwhile in young patients and determined the statisti-
cally difference between the untreated and treated groups. In Italy,
the participating Institutions regularly offer adjuvant chemotherapy
to patients presenting with the same high-risk characteristics.
Pro  adjuvant  treatment  outside  clinical  trial:  Adjuvant
chemotherapy is indicated for stage III soft-tissue sarcomas
of the extremities
R.S. BENJAMIN
(UT MD Anderson, Houston, USA)
The role of Adjuvant Chemotherapy in the treatment of patients
with soft-tissue sarcomas remains controversial despite a number of
randomized trials and several meta-analyses. Of the several, mostly
small, randomized trials of doxorubicin-based chemotherapy with
varying eligibility criteria regarding size, grade, and primary tumor
site, only one showed survival benefit. The NCI study was the first
to indicate that extremity tumors might benefit to a greater extent
than those  of other primary sites. Only one study showed better
disease-free survival in the observation group than in the chemo-
therapy  group,  whereas  8/9  studies  showed  better  disease-free
survival.  Moreover, while  none  of  the  studies  showed  improved
overall survival for the control group (one showed equal survival), 8/
9 showed improved survival in the adjuvant chemotherapy group.
Zalupsky and Baker were the first to perform such a meta-analysis
using the published data on 926 patients with extremity sarcomas
included in these studies. The meta-analysis demonstrated statisti-
cally  significant  improvement  in  both  disease-free  survival  and
overall survival. The absolute improvement in disease-free survival
at  10  years  was 15%  (p<.0001),  and absolute  improvement  in
survival at 10 years was 10% (p=.0005). This study was criticized
severely because it used published data rather than raw data.
Formal results of a meta-analysis of individual patient data showed
statistically significant improvement in local-relapse-free survival,
distant-metastasis-free  survival,  and overall  disease-free  survival
with a trend (p = 0.12) for improved survival. For the 886 patients
with extremity soft-tissue sarcomas, there was statistically signifi-
cant  improvement  in  distant-metastasis-free  survival,  in  overall
disease-free survival, and overall survival. The risk of relapse (local
and distant) decreased by 32% (absolute improvement at 10 years,
15%), the risk of distant metastasis decreased by 34% (absolute
Trial #/arm Eligible patients Follow-up (median) 5 yr% 10 yr%
LR RFS OS LR RFS OS
62771 control 172 >120 mos 30 46 62 30 45 54
CT 145 16 60 64 19 57 54
62874 control 67 88 mos 12 52 64
CT 67 12 56 65EORTC Abstracts 167
improvement at 10 years, 13%), and the risk of death decreased by
20% (absolute improvement at 10 years, 8%). The magnitude of
improvement is equivalent to that of 5-FU and leucovorin in colon
cancer or CMF in breast cancer.
There  is  only  one  modern  study  of  adjuvant  chemotherapy
reported  by  the  Italian  Cooperative  Group  in  the  March,  2001
issue  of the  JCO.  That  study, discussed  in further detail  at this
meeting  by  Dr.  Frustaci,  demonstrated  a  19%  overall  survival
benefit  at 4  years  for  the  patients  treated with  adjuvant chemo-
therapy, and it is the only study to target the appropriate group of
patients  for  an  adjuvant  chemotherapy  study:  those  with  deep,
high-grade  soft-tissue  sarcomas  of  the  extremities  >5  cm  in
primary size, i.e. current stage III. No one has ever claimed that
adjuvant chemotherapy  produces  substantial  survival  benefit  for
patients  with  soft-tissue  sarcomas.  Rather,  as  with  other  solid
tumors,  benefits  are  small  but  real,  and  the  chemotherapy  for
soft-tissue  sarcomas is highly toxic, and dose-intensive therapy is
required  for  optimum  efficacy.  The  neoadjuvant  strategy,
successful  in osteosarcoma and other tumors, allows selection of
patients who will benefit most from chemotherapy and is consid-
ered standard treatment for stage III tumors at our institution.
Adjuvant therapy for soft tissue sarcoma
K.H. ANTMAN
(Division  of Medical Oncology, Department of Medicine, Columbia
University, New York, USA)
Adjuvant chemotherapy is currently established in the treatment of
rhabdomyosarcomas, osteosarcomas, and Ewing’s sarcomas, but
remains unproven in other adult soft tissue sarcomas and therefore
should be used only in the context of a properly conducted clinical
trial. Given the significantly improved local control in the metaa-
nalysis,  however,  preoperative  chemotherapy  may  be  part  of  a
multimodality treatment plan for borderline resectable soft tissue
sarcomas.  The  risks  of  adjuvant  chemotherapy  trials  are  not
currently warranted in patients with low-grade lesions, given their
low probability of metastatic spread. Because surgical salvage of
pulmonary metastases or recurrent local disease is possible in some
patients, disease-free survival may be a less meaningful endpoint
than overall survival.
Of the 12 reported adjuvant studies, only 2 (one from the Rizzoli
Center in Bologna1 and the other from the Foundation Bergonie in
Bordeaux) show a significant overall survival advantage for chemo-
therapy.(table 1). One study (European Organization for Research
in the Treatment of Cancer (EORTC)) demonstrated a significant
improvement in local control for adjuvant chemotherapy, but no
overall survival benefit.2 Subset analyses in two additional studies
(from  M.D.  Anderson  Hospital3  and  the  National  Cancer
Institute4)  currently  indicate  a  significant  disease-free  survival
advantage for adjuvant chemotherapy in extremity lesions but no
significant  improvement  in  survival.  (While  the  NCI  reported  a
significantly  prolonged  survival  for  the  subset  of  chemotherapy-
treated extremity primaries on initial reports,5 survival is no longer
significantly different, due to late relapses.4 In the subset analysis of
the same NCI study for retroperitoneal sarcomas, the survival of the
control group is superior to the treatment group. Of the 12 rand-
omized trials, the survival of the observation arm exceeds that of the
chemotherapy arm in 3 studies (Mayo Clinic, Eastern Cooperative
Oncology Group (ECOG), Scandinavian study). Doxorubicin-asso-
ciated cardiotoxicity has occurred in about 10% of treated patients,
occasionally  contributing  to  treatment-related  deaths.  Based  on
these data, adjuvant chemotherapy should be considered investiga-
tional for adult soft tissue sarcomas of any primary site.
Table 1. Randomized adjuvant trials in high grade soft tissue sarcomas
%DFS %S
Institute Drugs N - + p - + p
EORTC2 ACVD 468 43 56 .007 56 63 NS
Extremities 233 64 64 NS 55 42 NS
Bordeaux7 ACVD 59 16 57 <.01* 53 87 <.01
Extremities 36 NA NA NA NA NA NA
Mayo Clinic8 AVDAd 61 68 65 NS 70 70 NS
Extremities 48 67 88 .08 83 63 NS
MD Anderson3 ACVAd 47 83 76 NS NA NA NS
Extremities 43 35 54 <.05 46 65 NS
NCI4,5,9,10 ACM
Trunk 22 47 92 <.01 61 82 NS
Retroperitoneal 15 NA NA NA 100 47 .06#
other 31 49 77 .075 58 68 NS
Extremities 67 28 54 <.05 60 54 NS
Scandinavia11 A 181 56 62 NS 70 75 NS
Extremities 155 NS NS NS NS NS NS
Pooled DFCI/MGH, ISSG, ECOG12 A 168 53 66 NS 65 68 NS
Extremities 72 64 79 NS 70 79 NS
GOG13 A 156 47 59 NS 52 60 NS
UCLA14 Extremities A 119 54 56 NS 74 78 NS
Rizzoli1,15 Extremities A 77 45 73 <.05 70 91 <.05
Abbreviations: DFS, disease-free survival; S, survival; -, without chemotherapy; +, with chemotherapy; EORTC, European Organ-
ization for the Research and Treatment of Cancer; DFCI/MGH, Dana Farber Cancer Institute/Massachusetts General Hospital;
ISSG, Intergroup Sarcoma Study Group; ECOG, Eastern Cooperative Oncology Group; GOG, Gynecologic Oncology Group;
UCLA, University of California at Los Angeles; NCI, National Cancer Institute; A, doxorubicin (doxorubicin); V, vincristine; Ad,
Actinomycin D; C, cyclophosphamide; D, dacarbazine; NA, not available; NS, not significant
*Authors reported metastatic-free survival.
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A meta-analysis  of  individual patient  data  from  all  randomized
adjuvant trials in sarcoma included data from 1568 patients. Adju-
vant chemotherapy improved the time to local and distant recur-
rence-free survival (hazard ratios 0.73 and 0.70 with p-values of
0.016 and 0.0003, respectively). However, for overall survival, the
absolute difference was a nonsignificant 4% advantage for chemo-
therapy and a hazard ratio of 0.89 (p = 0.12).6
Randomized trials thus far of ifosfamide and doxorubicin based
regimens are small with short follow-up, but will be of interest.
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Is Doxorubicin really the standard treatment of advanced
soft tissue sarcomas?
T. ALVEGAARD
(Southern Swedish  Regional Tumour  Registry, University  Hospital,
Lund, Sweden)
Introduction: Adult soft tissue sarcoma (STS) is considered to be
moderately  sensitive  to  chemotherapy,  with  some  reports
suggesting that tumours of high-grade malignancy respond better
than low-grade tumours. Doxorubicin and ifosfamide are generally
considered to be the most active agents, and aggressive combina-
tion  regimens  have  yielded  response  rates  of  around  45%.
However, the role of chemotherapy in prolonging survival is still
undefined in advanced disease and there is a need for the develop-
ment of new chemotherapy approaches. Etoposide is considered to
have low activity in adult STS. However, a recent study suggested
that the activity of etoposide is considerably higher when adminis-
tered as a prolonged infusion, taking advantage of the high cell
cycle phase specificity of this agent. Combined with a moderate
ifosfamide dose (4500 mg/m2), etoposide 600 mg/m2 given as a 72
h infusion yielded a 40% overall response rate in high-grade adult
STS. This  finding prompted the  Scandinavian Sarcoma Group
(SSG) to perform a prospective phase II trial to establish the level
of activity for this regimen in adult STS. The study also addressed
the possibility of dose escalation with the addition of granulocyte
colony-stimulating factor (G-CSF) (VIG regimen), and analysed
the  impact  of  G-CSF  on  haematological  toxicity.  Finally,  in
selected  patients,  the  study  analysed  disease-free  and  overall
survival after chemotherapy and surgical removal of all identifiable
disease.
Patients  and  methods: The  SSG  10/91  study  was  open  to
patients aged 15–70 years, with WHO performance status 0–2,
histologically proven soft tissue sarcoma and measurable locally
advanced  or  metastatic  STS.  Before  chemotherapy,  tumour
measurements were taken by CT of MRI (magnetic resonance
image) scans. Tumours of all malignancy grades were eligible,
but  small-cell  STS  (extraskeletal  Ewing’s  sarcoma,  primitive
neuroectodermal  tumours  and undifferentiated  variants)  were
ineligible, as were patients treated with radiotherapy to the indi-
cator lesion(s) during the preceding 2 months. Other require-
ments  were  adequate  renal  function  (creatinine  clearance
>70ml/min), WBC count >3.0 × 109/1 and platelet count >100
× 109/1.
Of 92 eligible patients (median age 51 years), 85% had tumours
of  high-grade  malignancy  and  82%  had  metastatic  disease.
Chemotherapy, the  baseline  dose,  consisted  of etoposide  600
mg/m2 as a 72 h infusion and ifosfamide 1500 mg/m2/day for 3
days, followed by G-CSF support. Stepwise 10% dose escala-
tions were performed depending on haematological toxicity. For
patients  considered  operable  after  induction  chemotherapy,
surgical  resection  of  all  identifiable  residual  tumours  was
attempted.
Results: Complete  and  partial  response  rates  were  11%  and
31%,  for an overall response rate  of 42%  (95%  CI 31–52%).
Forty-eight per cent of courses were dose escalated by a median
of  20%.  Complete  responders  had  significantly  higher,  and
patients  with  progressive  disease  had  significantly  lower,  dose
levels  than  other  patients.  None  of  the  20  patients  with  liver
metastases responded despite high dose levels. The addition of
G-CSF led to significantly higher dose levels, improved schedule
adherence  and  less  haematological  toxicity,  but  no  apparent
increase in response rate.
Discussion: The  present  study  demonstrated  a  high  overall
response rate (42%) for the present etoposide/ifosfamide combi-
nation. The present response rate is similar to that reported for
the most potent ifosfamide/doxorubicin combinations. However,
there is still controversy regarding whether combination chemo-
therapy is in fact superior to single-agent doxorubicin in adult
STS. In randomised studies, response rates are commonly lower
than in preceding phase II studies, as demonstrated in a recent
randomised EORTC study where no difference could be found
between doxorubicin alone, a doxorubicin/ifosfamide combina-
tion and CYVADIC. Considering the low level of non-haemato-
logical toxicity observed in this study, the VIG-regimen may beEORTC Abstracts 169
an  attractive  alternative  to  doxorubicin-containing  chemo-
therapy. The study supports the concept that surgical removal of
metastatic disease may prolong survival and that some patients
may be cured by metastasectomy. An escalated dose of etoposide
adm! inistered as a prolonged infusion may increase this agent’s
activity against STS, taking advantage of phase specificity. The
VIG  regimen  is  well  tolerated,  and  the  addition  of  G-CSF
appears to reduce haematological toxicity and the incidence of
neutropenic  fever,  to  allow  dose  escalation  and  to  improve
schedule adherence.
New drugs for treatment of metastatic soft tissue sarcomas?
A. LE CESNE
(Institut Gustave Roussy, Villejuif, France)
Results  of  first-line  chemotherapy  in adult  advanced soft-tissue
sarcoma remain disappointing. Only two drugs, doxorubicin and
ifosfamide, have demonstrated a consistent  single-agent  activity
yielding response rates of 10 to 25%. Dacarbazine seems to have
only a minor activity, if any, in leiomyosarcomas. If there is some
evidence of a dose-response relationship for doxorubicin and ifos-
famide in soft-tissue sarcoma, the objective response rate reported
with  doxorubicin alone have progressively decreased during the
last 10 years in trials coordinated by cooperative groups. In addi-
tion, despite higher response rates achieved in some studies, no
multidrug regimen has demonstrated any advantage in terms of
overall  survival,  when  compared  to  single  agent  Doxorubicin,
given at optimal doses. In the field of sarcoma new active drugs are
urgently needed. One of the major goals in clinical trials assessing
activity  of new  agents  in  these  well-known advanced chemore-
sistant tumours is to identify on a little cohort of patients potential
active drugs to definitive inactive agents. Due to the large hetero-
geneity of these tumours and patients included in phase II studies,
the  results  are  often  inconclusive  and  controversial.  Different
histological subtype behave like  different diseases with different
chemosensitivity  (liposarcoma  vs.  leiomyosarcoma)  Therefore,
response to  chemotherapy  (complete  and partial  response)  and
overall survival are not predicted by the same factors in retrospec-
tive analysis; in consequence of which, response should not be the
only end-point for evaluation of new agents and combinations in
this disease.
In terms of objective response (WHO criteria of response), which
defines  today  the  activity  of  chemotherapy  or  biotherapy,  the
results observed with new drugs are disappointing. None of these
following  agents:  taxanes,  liposomal  doxorubicin,  gemcitabine,
topotecan, ET-743 gives more than 15% of objective response in
palliative  situations.  However,  if  we  carefully  analysed  these
studies, a relevant activity of these drugs could be find in some
selected histological subtype of sarcomas: gemcitabine in uterine
leiomyosarcomas, ET-743 in leiomyosarcomas, paclitaxel in angi-
osarcoma. The era of selected drugs for selected sarcomas is open
with  these  new  drugs  and by  the  emergence  of  new  concepts:
specific agent for specific tumour targets. The dramatic activity of
STI-571  on  GIST  (histological  subtype  uniformly  resistant  to
doxorubicin  and/or  ifosfamide  regimens)  and  the  interesting
mechanism of action of rosiglitazone in dedifferenciated abdom-
inal liposarcoma have to modify our strategic approaches in the
management of patients with advanced sarcomas.
In a context of palliative therapeutic approaches, we have to favour
a prolonged stable disease achieved without major toxicity over
transient partial responses achieved at the cost of life-threatening
side effects. The number of patients experiencing prolonged stabi-
lisation of their disease in phase II and III trials can modify the
progression free survival of patients included in these trials and
this clinical parameter have to take into consideration for evalua-
tion of activity of new drugs. The WHO criteria of response could
integrate in the next future the tumour status at the end of the
planned chemotherapy schedule and the median duration of the
disease stabilisation in metastatic soft tissue sarcoma, since a high
proportion (30 to 60%)  of patients with  metastatic  soft tissue
sarcomas experiences this type of response with tumour changes
insufficient to enable classification into distinct response catego-
ries (CR, PR and PD).
With the emergence of inhibitors of angiogenesis, new non cyto-
toxic agents and new cellular targets for gene therapy programs
and cancer vaccines, one of the objectives of the next century
will  undoubtedly  be  to  significantly  prolong  life  of  these
patients, by maintaining a ‘dormancy-state’ in non symptomatic
lesions. On the other hand, dose-intensified combinations, still
as part of study protocols, had to be always proposed in highly
selected  patients  with  highly  chemosensitive-advanced
sarcomas.
In  addition,  the  well-known  discrepancy  between  clinical  and
histological  response  in  locally  advanced  soft  tissue  sarcoma
treated with preoperative chemotherapy can be easily applied to
metastatic sarcomas. Histological responses could be a more accu-
rate predictor of chemosensitivity than clinical responses, making
difficult to evaluate the actual impact of these new drugs on disease
free and overall survival of these patients.
The experience  of SFOP in the treatment of Ewing/PNET
family of tumours
O. OBERLIN
(Institut Gustave Roussy, Villejuif, France)
The  purposes  of  the  SFOP  EW88  study  were  1)  to  improve
survival rates in patients with Ewing’s sarcoma (ES) or peripheral
neuroectodermal tumours (PNET) using semi-continuous chem-
otherapy  and  performing  resection  of  the  primary,  as  often  as
possible, 2) To identify prognostic factors. 141 patients with local-
ised tumour were entered onto the trial between January 1988 and
December  1992.  Induction  therapy  consisted  of  5  courses  of
Cytoxan, 150 mg/m2 × 7 days, followed by Doxorubicin, 35 mg/
m2 IV on day 8. Surgery was recommended whenever possible.
The delivery of radiation therapy was based on the quality of resec-
tion and the histological response to CT. Maintenance chemo-
therapy  consisted  of  vincristine  +  actinomycin  and  cytoxan  +
doxorubicin.
Results: After  a  median  follow-up  of  8.5  years,  the  projected
overall survival at 5 years was 66% and disease-free survival (DFS)
was  58%.  In  patients  treated  by  surgery,  only  the  histological
response  to  CT  had  an  influence  on  survival:  75%  DFS  for
patients with a good histological response (less than 5% of cells),
48%  for  intermediate  responders  and  only  20%  for  poor
responders (> 30% of cells), p < 0.0001. The tumour volume by
itself had no influence on DFS in these patients. In contrast, the
tumour volume had a strong impact on DFS in patients treated by
radiation therapy alone. Age had no impact on outcome. As size of
the  primary  and  response  to  chemotherapy  are  independently
correlated with outcome. We could identify 3 risk groups on the
base of these factors:
— The  standard  risk  group  included  the  tumours  with  good
response to chemotherapy (less than 5% viable cells) and the
small  unresected  tumours  but  who  had  good  clinical
response. Its disease-free survival was 75%.
— The high risk group included the tumours with clinically or
histologically  poor  response  to  chemotherapy  (with  more
than 30% viable cells). Its disease-free survival was only 13%.
— The intermediate risk group included the tumours with inter-
mediate response to chemotherapy (between 5 to 30% viable
cells) and the large unresected tumours but which had a good
clinical response. It’s disease-free survival was 44%.
The subsequent SFOP EW93 study was based on this risk groups.
In the intermediate risk group, the role of the adjunction of VP16
+ ifosfamide to the previous chemotherapy was evaluated. In the170 EORTC Abstracts
high risk group, the value of high dose chemotherapy with stem cell
support was addressed. The preliminary results of this study will be
presented.
Lessons from the EICESS 92 study
H. JÜRGENS, B. FRÖHLICH, S. AHRENS, M. PAULUSSEN,
A. ZOUBEK, I. LEWIS, P.A. VOÛTE, W. WINKELMANN, B.
DOCKHORN–DWORNICZAK & A.W. CRAFT
(Department of Paediatric Haematology and Oncology, University of
Münster, Germany)
The EICESS 92 protocol for the treatment of patients (pts) with
localised and primary metastatic Ewing tumours (ET) was initi-
ated in 1992 as a cooperative project of the German Society of
Paediatric Oncology and Haematology with its associated part-
ners  in  Austria,  the  Netherlands,  and  Switzerland,  and  the
United Kingdom Children’s Cancer Study Group. Between 04/
92 and 12/99, 643 ET pts with a median age of 15 (0,8–35) years
and a female-to-male ratio of 40% females were registered. The
primary tumour was mostly localised in the pelvis (25%) and the
femur (19%). According to tumour volume (TV) and the pres-
ence  of primary metastases  as established  risk  factors,  the  pts
were allocated into two risk strata. The standard risk (SR) group
included 154 pts with localised ET and a TV <100 ml, the high
risk  (HR) group, 489  pts  with  a TV >100  ml  and/or primary
metastatic  disease.  SR  pts  were  randomised  for  maintenance
chemotherapy to receive the  standard VAIA  (vincristine, adri-
amycine, ifosfamide, actinomycin D) or the less intensive VACA
regimen  (vincristine,  adriamycine,  cyclophosphamide,  actino-
mycin d), and HR pts were randomised for standard VAIA versus
more intense EVAIA (VAIA plus additional etoposide) chemo-
therapy.
After a median time under study of 52 months, overall survival
(OAS) and event free survival (EFS) five years after diagnosis
were 0.69 and 0.59 in pts with localised ET and 0.42 and 0.32
in pts with primary metastases. In pts with localised ET the anal-
ysis according to risk groups shows a significantly better five-year
EFS in SR pts (0.67) compared to HR pts (0.55) (p = 0.0018).
There was no significant difference in outcome between VAIA
and VACA in the SR group and between VAIA and EVAIA in
the  HR group, but  life  table  analyses show in  both groups a
tendency for a better five-year EFS in the more intensive treat-
ment arms (SR: 0.77 (VAIA) vs. 0.61 (VACA) (p = 0.32); HR:
0.61 (EVAIA) vs. 0.50 (VAIA) (p = 0.3577)). Further analyses
showed a significant better outcome for pts with small ET (0.69
(<100  ml)  vs.  0.61  (100–200  ml)  vs.  0.51  (>200  ml),  p  =
0.0017) and for pts with good histological response to chemo-
therapy (0.72 (<10% viable tumour cells) vs. 0.48 (>10% viable
tumour cells), p = 0.0001). Multivariate Cox regression identi-
fied the histological response to chemotherapy as most impor-
tant risk factor, compared to age, TV, and primary tumour site
(risk ratio: 2.39 vs. 1.49 vs. 1.43 vs. 1.62). A further prognostic
factor  is  the  modality  of  local  therapy. There  is  a  significant
advantage for surgical procedures with or without radiotherapy
(five-year EFS: 0.65 (surgery +/- radiotherapy) vs. 0.47 (radio-
therapy), p = 0.0001), with a higher incidence of local (9% vs.
3%) and combined relapses (10% vs. 3%) in the group of irradi-
ated ET pts. According to toxicity, WHO grade 4 neutropenia
was highest in pts randomised for EVAIA, but this was not asso-
ciated with a higher incidence of severe infections or secondary
malignancies.
In conclusion the results regarding randomised treatment strate-
gies at present show no statistical significance. Longer follow-up is
needed for definitive results. The preference for surgical proce-
dures has improved the safety of local control.
Supported by Deutsche Krebshilfe, EU-BIOMED, and Sabrina Forsc-
hungsfond.
Ewing’s sarcoma: the Italian experience and strategy
PIERO PICCI,  GAETANO  BACCI, STEFANO FERRARI  &
MARIO MERCURI
(For the Italian Sarcoma Group)
From  1972  to 1997,  494  patients  with  non-metastatic  Ewing’s
family  tumors,  comprising  Ewing’s  sarcoma,  Askin  tumor  and
peripheral  neuro-ectodermal  tumor  (PNET),  were  treated
according to 5 protocols. The strategies  of chemotherapy treat-
ment changed over the years: from 1972 to 1988, a 3-drug regimen
with vincristine (V), doxorubicin (A) and cyclophosphamide (C)
gave significantly worse oncologic results (10-yr DFS 28%) than
those obtained with a 4-drug regimen with V-A-C and actinomycin
D (Act) used either as adjuvant (10-yr DFS 52%) or as neo-adju-
vant chemotherapy (10-yr DFS 46%). From 1988 ifosfamide (I)
and etoposide (E) were added to the  V-A-C-Act  regimen. In a
study conducted between 1988 and 1991 Ifosfamide and Etopo-
side  were used  in  the  maintenance  phase  added to  V-A-C-Act
without  improving  oncologic  results  (5-yr  DFS  54%).  In  the
subsequent study Ifosfamide was used from the induction phase
added to V-A-C-Act, and Etoposide was used in the maintenance
phase. With this protocol, 3-yr DFS was 78%. Strategies for local
control also changed: in the first two adjuvant protocols radiation
therapy (RxT) alone was used in 67%, and 49% of patients respec-
tively, whereas in the last neoadjuvant protocol 72% of patients
underwent surgical treatment. From 1993, a separate protocol for
high-risk tumors (pelvis, axial skeleton and all sites metastatic) was
activated.
A retrospective analysis on all patients, showed the importance of
surgical treatment in local control and the strong prognostic signif-
icance  of  tumor  necrosis  induced by  primary  chemotherapy  in
surgically treated patients. In the first protocols the axial location
of  the  tumor  was  an  adverse  prognostic  factor,  but  in  the  last
protocol axial and extremity tumors did not show a significantly
different oncologic outcome.
These data, and, particularly, the grade of chemotherapy induced
necrosis,  were used  to  define  the  different risk  groups  and the
ongoing protocols.
Abstracts—Posters
Long-term  outcome  of  patients  with  malignant  fibrous
histiocytoma
D.  ZURAKOWSKI,  M.  PEIPER,  C.  ZORNIG,  W.T.
KNOEFEL, & J.R. IZBICKI
(Department of Surgery, University Hospital, Hamburg, Germany and
Harvard Medical School, Boston, Massachusetts)
Purpose: To  determine  outcome  of  patients  with  malignant
fibrous histiocytoma (MFH) of the extremities and trunk.
Patients: From a  consecutive  series  of  417  patients  with  soft-
tissue sarcoma operated on 1988–98, 86 patients had MFH (45
males, 41 females). Mean ± standard deviation age was 56 ± 16
years. Mean follow-up was 5.2 ± 3.4 years for all patients; 7.5 ±
2.6 years for the survivors.
Methods: Retrospective cohort study. Survival, freedom from LR
and metastases were determined by Kaplan–Meier method with
95% confidence intervals (CI). Cox model and hazard ratio (HR)
was  used  to  determine  risk  factors.  Covariates  included  age,
gender,  location,  tumor  grade,  size,  depth,  resection  quality,
metastases or lymph nodes at presentation.
Results: Forty-one patients died (36 by tumor), 36 had LR, 30
developed metastases.  Kaplan–Meier disease-free  survival (95%
CI) was 90%  (85–95) at 1 year, 65% (55–75) at 5 years, 52%
(40–64) at 10 years. Multivariate risk factors were tumor size (HR
=  4.7),  depth  (HR  =  3.2),  and lymph  nodes  (HR  =  5.8)  (all
p<0.01).  Freedom  from  LR  was  75%  (68–83)  at 1  year, 60%
(50–70) at 5 years. Resection quality was the only multivariate riskEORTC Abstracts 171
factor of LR (HR = 6.8, p<0.001). Freedom from DM was 82%
(75–90) at 1 year, 63% (53–73) at 5 years and 10 years. The only
risk factor of DM was tumor depth; patients with subfascial tumors
fared worse (HR = 2.2, p = 0.007).
Discussion: MFH patients with deep or large tumors have worse
outcome, particularly given the development of DM during follow-
up. These patients may benefit most from adjuvant radiation.
Perineal soft tissue sarcoma: a retrospective analysis of 22 
patients.
F. DURAME*‡, A. CALVACANTI*‡, A. LE CESNE*, C. LEP-
ECHOUX*, P. TERRIER*, D. VANEL* & S. BONVALOT*‡
(Department of Surgical Oncology‡, Sarcoma Unit* Institut Gustave-
Roussy Rue Camille Desmoulins. Villejuif France)
Objective: to clarify particularities of perineal soft tissue sarcoma.
Method: retrospective analysis of 22 patients with a median age
of  34  years.  Stromal  tumours,  paediatric  sarcoma  and  pelvic
tumours with perineal extent were excluded.
Results: Time to diagnosis was 6 months after non-specific signs.
Ischio-rectal topography was the most frequent localisation (27%).
68% were high-grade sarcoma. Rhabdomyosarcoma (36%) and
leiomyosarcoma  (22%)  were  the  main  histological  subtypes.
Lymph-nods were involved in 27%  cases. 23%  of patients  had
synchronous  metastasis.  86%  of  patients  had  inadequate  first
surgery.  Surgical  re-excision  allowed  an  R0  resection  in  90%
patients (tumours completely surrounded by uninvolved tissue).
Local control is influenced by quality of excision (R0 versus R1
R2). The median overall survival (25  months) is  influenced by
initial stage, grade and depth of the tumour.
Conclusion: Primary perineal sarcoma is a rare aggressive entity
with dismal prognosis. An initial biopsy is necessary to avoid inad-
equate surgery. Re-excision allows an R0 resection in 90% cases
but  is  associated  with  more  sequels  than  performed  initially.
Impact of induction chemotherapy must be evaluated.
Provincial  variations  in  soft  tissue  sarcoma  (STS)  treat-
ment and outcomes
C. DE GARA
(Cross Cancer Institute, Edmonton, Canada)
Purpose: This project examines intra provincial variations in Soft
Tissue  Sarcoma  (STS)  Treatment  and  Outcomes.  Level  I
evidence favours limb  sparing surgery plus  postoperative radio-
therapy  and  single  agent  adjuvant  chemotherapy.  Institution
specific level V evidence tend to advocate numerous alternatives
Patients/Subjects: All  STS  cases  diagnosed  in  Alberta  between
1990 and 1998 were identified from the Alberta Cancer Registry,
a population based cancer registry. Population-based data may be
less prone to selection, referral and treatment biases inherent in
single center series. Healthcare in Alberta is universal, government
funded and single  tiered. Alberta  has 2  regional cancer centres
(north and south). Although the complex multi-disciplinary nature
of STS ensures all cases are managed at regional cancer centres,
treatment and outcomes variations may exist. Variations in patient
demographics, tumour characteristics, treatment and survival were
examined.
Results: There were 327 STS diagnosed, 61% were > 50 years,
with  MFH (29%), leiomyosarcoma (14%) and myxoid liposar-
coma (8%) being the commonest morphologies and lower limb
(43%), upper limb (15%) and pelvis (14%) being the commonest
sites.
Discussion: Potentially important STS treatment differences were
observed across Alberta. These may translate into short term but
not long-term survival differences. Population based research may
have a significant role in STS management.
Deep soft tissue sarcomas of the extremities. Management
analysis of 120 patients
Y. KOLLENDER, J. BICKELS, O. MERIMSKI, J. ISAKOV, G.
FLUSSER, A. NIRKIN, & I. MELLER.
(The National Unit of Orthopedic Oncology. Department of Surgery B.
Sourasky Medical Center, Tel Aviv Israel)
The  national  Unit  of  Orthopedic-Oncology,  Tel-aviv  Medical
center, Tel-aviv, Israel Deep soft tissue sarcomas of the extremities
often present as a big mass near the major neurovascular bundle.
For that reason in some cases free marginal resection cannot be
achieved  without  causing  major  morbidity  to  the  patient.  New
neoadjuvant  modalities  as  chemotherapy  or  regional  therapy
(I.L.P) are given to patient in attempt to achieve the goal of safe
resection  and avoid major disability  or high rate of local recur-
rence.
Materials  and  methods: From 1.1992  to 12.1997,  120  patients
were diagnosed with  deep soft  tissue  sarcomas.  There  were 67
males and 53 females whose age ranged from 2 to 90 (median, 56
years). 96 tumours presented in the lower extremity and 24 in the
upper limb. 90% of the tumours were graded as high grade histo-
logically. 53% of the tumours were adjacent to the major neurov-
ascular bundle. Tumours that were extremely large or close to the
neurovascular  bundle  were  treated  with  neoadjuvant  chemo-
therapy or isolated  limb  perfusion. Wide surgical  resection  was
attempt in all cases. Radiation therapy was added post surgery in
most cases. Adjuvant chemotherapy was given according to the
treatment protocols.
Results: 22 patients were given neoadjuvant chemotherapy and
24 patients underwent I.L.P. In 78 patients wide margins were
achieved, radical margins in 11 (7 amputations) and 28 marginal
margins.  Adjuvant chemotherapy was  given  to  23  patients  and
radiation to 77 patients. 16 patients had local recurrence. At most
recent follow up 28 patients died of systemic disease (23%). Only
3 patients (14%) from the neoadjuvant chemotherapy group died
from systemic disease.
Conclusions: The use of neoadjuvant modalities as chemotherapy
or Isolated limb perfusion, attempted wide excision, and adjuvant
chemo and radiation therapy achieve low recurrence rate in deep
soft tissue sarcomas of the extremities. Neoadjuvant chemotherapy
may improve survival.
A  20-year  review  of  haemangiopericytoma  in  Auckland,
New Zealand
M.F. BORG & C.S. BENJAMIN
(Royal Adelaide Hospital, Department of Radiation Oncology, North
Terrace, Adelaide, South Australia)
Tumour grade Treatment Survival
Low High unstated CT+RT+  only 3 year5 year SxRT+SxSx
Northern Alberta 27% 41% 32% 4% 29% 46% 68% 63%
Southern Alberta 24% 17% 59% 37% 12% 30% 75% 62%
p value ns ns sig sig sig sig sig Ns172 EORTC Abstracts
Purpose: The records of all patients registered with a histological
diagnosis of haemangiopericytoma in Auckland between 1970 and
1990 were reviewed retrospectively, with the aim of determining
the natural history of the disease and the response to various treat-
ment modalities. A total of 24 patients were identified, having a
median age of 45 years.
Patients/Subjects: Twenty-one  patients  (87.5%)  underwent
surgery; the remaining three were deemed to be unfit for surgery.
Seven  patients  (29%)  were  treated  with  surgery  alone;  nine
(37.5%)  received  a  radical  course  of  radiotherapy  and  three
(12.5%) received palliative radiation therapy for pain relief and/or
dyspnoea. Five patients (21%) received chemotherapy during the
course of their disease.
Results: Eight of the 24 patients (33%) were alive and disease
free, 13 (54%) having died and three (13%) being lost to follow-
up. Seven patients (29%) died as a result of metastatic disease.
Three of the seven (43%) who were treated with surgery alone are
known to be alive and disease free. The three patients who had
received  palliative  radiotherapy,  died  within  2  months  of
completing the latter treatment. Five of the nine patients (56%)
receiving a course of radical radiotherapy are alive and disease free
at present. No local recurrence was noted following surgical exci-
sion and postoperative radical radiotherapy, whilst eight (67%) of
those  initially  treated  by  excision  alone  developed  recurrent
disease. None of the patients treated with chemotherapy obtained
significant palliation.
Discussion: Results  suggest  that  adequate  surgical  excision
followed by postoperative radiotherapy is effective in controlling
haemangiopericytoma  and  that  metastatic  disease  is  at  present
invariably fatal. The role of chemotherapy needs further investiga-
tion.
Ossifying fibromyxoid tumour of soft tissues
S.  HOLCK1,  J.G.  PEDERSEN2,  T.  ACKERMANN3  &  S.
DAUGAARD4
(1Department of Pathology, Hillerød Hospital, 2Department of Orthoped-
ic  Surgery  &  4Department  of  Pathology,  University  Hospital,  Cph,
3Department of Surgery, Frederikssund Hospital, Copenhagen, Denark)
Purpose: Ossifying fibromyxoid tumour (OFMT) is a rare lesion
of  soft  tissues.  Thus,  in  our  institutions,  each  receiving  some
30.000  histological  specimens  per  year,  we  have  encountered
merely one such case each since its original description in 1989.
We wish to present these 2 cases, which show features typical of
this distinct entity, but also add unusual details.
Patients: #1: 55-year-old female with a tumour of the back and
right axilla. The tumour measured 12 cm, had a heterogeneous
cut  surface  regarding  consistency  and  colour.  #2:  62-year-old
female  with  a  tumour  at  the  base  of  left  thumb.  The  tumour
measured 1.7 cm and had a lobular contour. The general histo-
logical pattern of both tumours featured bland, round to plump
spindly cells arranged in lobules. Mitoses were few in #1; in #2 up
to 4 mitoses/HPF were counted. Lesional cells were Vim+ and S-
100+, #2 also desmin+. Bony spicules were seen centrally as well
as peripherally  in #2. Electron  microscopy showed cytoplasmic
projections with intermediate  filaments and focal duplication of
basement  membranes.  Fibronexus-like  structures  were  seen  in
#2.
Discussion: The morphology of both cases was compatible with
OFMT, but displayed in addition following unusual traits:  #1:
gigantic size, ossification confined to central portions—#2: periph-
eral location of the tumour, high mitotic index, presence of fibron-
exus-like  structures.  The  latter  is  characteristic,  though  not
specific, of myofibroblasts, and thus may provide information as to
the  histogenesis  of  OFMT. Correspondingly,  a  myofibroblastic
derivation  has  previously  been  proposed,  though  most  authors
favour a neural origin.
Multiple myxoid liposarcomas or metastases? P53 and LOH
analysis.
A.N. VAN GEEL, M.A. DEN BAKKER* & W.N.M. DINJENS*
(Dept of surgical oncology and *pathology, University Hospital Rotter-
dam/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands)
Purpose: A study of multiple deposits of liposarcoma in an single
patient to determine if these deposits are primary lesions or metas-
tases.
Patient: A 32 year old female was seen in our clinic with a recur-
rent liposarcoma  in  the  knee  and deposits  in  the  left  paracolic
region, right ovary, hilus of the liver, right kidney, left breast and
anterior mediastinum. After doxorubicin (7 cycles) radical resec-
tion of all deposits was achieved by sternolaparotomy. Two years
later a retroperitoneal recurrence was removed and currently, 4
years after initial presentation she is suffering from am retroperito-
neal and mediastinal recurrence.
Results: DNA  was  extracted  from  formalin-fixed,  paraffin
embedded  tumour  tissue  from  the  various  recurrences  and
analysed for the presence of p53 mutations and loss of heterozy-
gosity (LOH) using 20 polymorphic markers.
Discussion: Because soft tissue metastases from myxoid liposar-
coma are highly uncommon it was thought that this could be a case
with multiple  primary liposarcomas. We sought to establish  the
relationship between the various liposarcoma deposits with molec-
ular techniques. No p53 aberrations were found and LOH was not
observed in any one of the tumour samples.
We  conclude that  LOH-analysis  is  not  a  suitable  technique  to
determine whether metastases  in soft tissue from a liposarcoma
really are metastases and not synchronous primary liposarcomas.
Secondly, the absence of LOH indicates that other, possible more
specific genetic events underlie myxoid liposarcomas.
Soft tissue sarcomas of the head and neck
C.  LAJER1,  S.  DAUGAARD2,  H.S.  HANSEN3,  J.
KIRKEGAARD1 & M. CHRISTENSEN1
(1Dept.s of Otorhinolaryngology and 2Pathology and 3Oncology, Rig-
shospitalet (University Hospital), Copenhagen)
Purpose: To report our experience with malignant and borderline
soft tissue tumours (STT) of the head and neck region 1977–2000,
with  the  additional intention of establishing  a foundation for a
future database of these lesions.
Material and methods: So far, 34 records from adult patients have
been  identified  from  the  archives  and  pathological  specimens
reviewed.
Results and discussion: Three patients were excluded for having
sarcomatoid carcinomas. Remaining were 20 men and 11 women,
median age 56 years. The most common location was the nasal
cavity and paranasal sinuses, followed by the maxilla and alveolar
ridge. After review, which changed the diagnosis in 9 cases (26%),
the most common histological diagnoses were leiomyosarcoma (6
cases), synovial sarcoma (4) and hæmangiopericytoma (4). Like
others, we saw no liposarcomas, but a relatively high proportion of
borderline malignancies. 28 patients underwent primary surgery
with curative intent, while 3 patients had a biopsy only. 8 received
post-operative irradiation and 1 patient received irradiation as sole
treatment. Only 4 patients received adjuvant chemotherapy. Mean
follow up time  was 28  months  (range 1–127  months), with 19
patients (61%) recurrence free; 8 of these had borderline malig-
nancies (4 hæmangiopericytomas, 3 hæmangioendotheliomas, 1
aggressive fibromatosis). 9 (29%) had died from their disease—5
of them with distant metastases and only 2 with lymph node metas-
tases.
Conclusion: Head and neck STT differ in their composition from
those of other sites. Because of their rarity, they present a diag-
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centralized and clinical databases established in order to collect
experience, preferably in intergroup trials.
The  treatment of aggressive  fibromatosis at a specialized
centre.
C.A.  GRAFTON*,  K.  GODDARD*, C.  BEAUCHAMP#,  K.
MORTON# & M. KNOWLING*
(*Vancouver Cancer Centre, British Columbia Cancer Agency (BC-
CA), and #Vancouver General Hospital, B.C., Canada)
Purpose: At BCCA aggressive fibromatosis  is treated using the
same oncological principles as sarcomas. The following is an audit
of this  approach compared with  patients  treated elsewhere  and
seen later in the course of the disease. Patients over 16 years old
seen at BCCA from 1980 to 1993 were reviewed.
Method: All new patients  had clinical examination and CT or
MR  scans  prior  to  biopsy.  Patients  with  a  biopsy  or  excision
performed  elsewhere  were  also  scanned.  All  pathology  was
reviewed at BCCA. Treatment was by wide excision with radio-
therapy when either surgical margins were narrow or to enable
limb sparing. For patients previously resected and found to have a
marginal excision, a re-excision of the surgical bed was performed
and treatment considered as of BCCA.
Results: A total of 48 patients were seen and the disease specific
survival is 46/48 (92%). The disease-free survival is 48% at 5 years
and 90% of relapses were within 2 years. Of patients treated at
BCCA 3/13 relapsed against 26/35 treated elsewhere. Of patients
treated with radiotherapy 2/12 relapsed against 27/36 without radi-
otherapy.
Discussion: The indication is that a specialized centre may attain
better local control and radiotherapy may have a central role. We
have  not  assessed  the  toxicity  and resultant  function  from  this
approach to a disease, which is rarely fatal.
Fibromatosis of the neck: a review of 18 cases
C.K. HUANG, S.D. NELSON & T. CALCATERRA
(University of California Los Angeles Medical Center)
Purpose: Fibromatosis is a histologically benign, clinically aggres-
sive  tumor  with  a  tendency  to  invade  adjacent  structures  and
locally recur. Fibromatosis of the neck is challenging as nearby
important structures increase morbidity and make surgical exci-
sion difficult. We report a series of fibromatosis of the neck and
discuss the challenges in its treatment.
Patients: The study consisted of 18 patients with fibromatosis of
the neck seen at our institution. The clinical data was collected
retrospectively from patient charts and all slides were reviewed by
one pathologist.
Results: Patient age ranged from 20–72 with a female to male
ratio of 13 to 4. All patients presented with mass, about half (n =
9) had accompanying pain, and a few had decreased mobility or
Horner’s syndrome. All patients underwent an attempt at a wide
surgical  excision.  Gross  margins  could  not  be  obtained  in  5
patients whose tumor invaded the spine or base of skull. Micro-
scopically negative margins were obtained on only three patients.
Three patients received adjuvant radiation therapy. There was an
overall recurrence rate of 47% (n = 8) after an average disease free
interval of 16 months. Recurrent disease was treated with re-exci-
sion, re-excision with radiation, or chemotherapy.
Discussion: There  is  no  consensus  on  the  best  treatment  for
fibromatosis of the neck. Though the current recommendation is a
wide surgical excision, it cannot be shown to eliminate disease or
prevent  recurrence.  A  radical  surgery  is  often  limited  by  the
anatomy of the neck. Therefore, other treatment methods should
be considered for fibromatosis of the neck.
Soft tissue sarcoma of the extremities and trunk—outcome
of patients treated within 6 years under the same strategy.
M.  PEIPER,  C.  ZORNIG*,  D.  ZURAKOWSKI,  W.T.
KNOEFEL, C. BLOECHLE, E.G. ACHILLES & J.R. IZBICKI
(Departments of Surgery, University Hospital Hamburg and *Israeli-
tisches Krankenhaus, Hamburg, Germany)
Introduction: Most outcome studies  to determine  the effective-
ness of soft tissue sarcoma (STS) therapy span a long period of
time and involve several different therapeutic strategies.
Methods: From March 1988 to March 1994, 101 patients under-
went  surgery  for  primary  STS  of  the  extremities  or  trunk.  All
patients were operated on by the same surgeon. Early re-excision
was  made  after  inadequate primary  resection.  Stepwise  logistic
regression was used to identify the important predictors of death.
Cox  regression  models  and Kaplan-Meier  curves  were  used  to
assess time-related survival.
Results: Mean age of patients was 48 (range 15–84) years, 50%
were female. The STS was located at the proximal extremity in
61% of all patients; 23% of the sarcomas were at the trunk, and
16% were distributed in the distal extremities. In 77% of patients,
a resection with wide margins (R0) was achieved. In cases of R1 (n
= 19) and R2 (n = 4) patients either denied reoperation or a palli-
ative resection was performed. Postoperative radiation therapy and
chemotherapy were administered in 44% and 17% of all patients,
resp.  The  overall  survivorship  was  83.2%  (mean  follow-up  36
months). The survival rate was 90% at 1 year and 84% at 3 years.
Multivariate risk factors influencing survival were tumor grade (p
= .02), positive regional lymph nodes (p<.01), and location (p =
.03). Local recurrence was not associated with increased mortality
(p = .18). Patients with positive regional lymph nodes (p<.001),
distant metastases (p<.001), and G3 tumors (p<.01) had shorter
survival times.
Conclusions: Improvements in survival of patients with STS can
be achieved with the use of complete excision within the anatom-
ical  compartment  at  initial  surgery.  Radiation  therapy  shall  be
performed  in  all  cases  of  R1/R2  resections.  High-risk  patients
without wide resection margins and G3 tumors may benefit most
from this strategy.
Central nervous system metastasis from sarcomas: still an
unresolved problem
A.  COMANDONE,  A.  BOGLIONE,  O.  DALCANTON,  S.
CHIADÒCUTIN, C. OLIVA & P. BERGNOLO.
(Oncologia, Ospedale Gradenigo, Torino, Italy)
Soft  tissue  and  bone  sarcomas  rarely  cause  CNS  metastasis
(<1%). We reviewed 19 cases of brain and medullar metastasis
between  1990  and 2000.  There  were  10  males  and 9  females,
median age 48 (17–66). PS 1–3 ECOG. Histological subtypes: 7
leiomyosarcomas, 3 MFH, 2 undifferentiated, 1 clear-cells, 1 pleo-
morfic liposarcoma, 1 schwannoma, 1 synovialsarcoma, 1 chond-
rosarcoma,  1  small-cell  bone  sarcoma,  1  extraosseous  Ewing
sarcoma. The two last determined medullar metastasis. Primary
sites  were: 7 visceral  organs, 9 extremities,  2  trunk, 1  vertebral
body. 15 pts had a high-grade sarcoma. 9 pts had multiple brain
mets  and  10  unique.  All  patients  were  heavily  pre-treated:  all
received  surgical  treatment  of  primary  tumour  and  7  adjuvant
chemotherapy (CT). All 19 patients were treated with CT when
disease relapsed, 7 received a second-line therapy, 6 had a third-
line. Median time to relapse was 30 months (11–54). 16 patients174 EORTC Abstracts
received palliative CNS radiotherapy (RT) (15 Gy). Five patients
had platinum-based  CT. All  patients  had anti-oedema therapy.
Median survival  from  diagnosis  of  CNS  mets  was  4.1  months
(2–10). No responses  were recorded. CNS mets  from sarcoma
have  a  poor  prognosis,  with  very  short  survival.  No  significant
responses can result after CT or RT. Moreover CT and RT do not
seem to offer better results than best supportive therapy.
National retrospective study of radiation-induced soft tissue
sarcoma in the netherlands.
E.A.  BAARTMAN*,  A.N.  VAN  GEEL*,  F.  VAN  CO-
EVORDEN, J.W. COEBERGH & F.E. VAN LEEUWEN
(*Dept of surgical oncology and radiotherapy, University Hospital Rot-
terdam/Daniel den Hoed Cancer Center and the Dutch Soft Tissue Sar-
coma Group)
Purpose: To evaluate the occurrence of soft tissue sarcoma (sts)
after radiation therapy and to investigate treatment strategy and
prognosis.
Patients  and  methods: In  this  Dutch  multi-institutional  study
records  of  101  (preliminary)  patients  were  retrospectively
reviewed. Patients were eligible if they had a diagnosis of STS that
occurred after sufficient latency following radiation therapy for a
histologically proven distinct primary tumour and originated in the
vicinity  of  the  irradiated  area.  The  investigated  parameters
included  age  at  diagnosis,  type  of  irradiation,  dose  delivered,
tumour histology, anatomic location and interval between these
tumours, treatment of the sarcoma, histology and follow-up.
Results: Preliminary results showed that the median age at the
time of diagnosis of the primary was 47.3 years (11–86) and the
median interval between irradiation and diagnosis of the sarcoma
was 11.2 years (2–38). The median dose delivered to the primary
was 47.3 Gy (16–75). Seventeen patients had developed a STS on
the edge of the radiation field. Nineteen patients were seen with an
angiosarcoma of the breast after breast cancer. Survival after diag-
nosis of sarcoma was generally poor (median 29 months).
Discussion: The induction of soft tissue sarcoma after radiation
therapy is a rare but serious complication. Nowadays follow-up is
sufficient to evaluate the different aspects of postradiation STS as
will be presented in this study and side studies as case control-and
dose deliverance studies are in progress.
Gastrointestinal stromal tumours
A.M. MOGENSEN, S. HOLCK* & S. DAUGAARD
(Dept. of Pathology, Rigshospitalet, Copenhagen & *Dept. of Patholo-
gy, Hillerød Hospital, Hillerød, Denmark)
Purpose: The  knowledge  that  gastrointestinal  stromal  tumors
(GIST) usually express the c-kit proto-oncogene product, a trans-
membrane tyrosine-kinase receptor (CD117), has now established
them as a distinct entity. Hence we found it of interest to review
our cases.
Methods: Pathological  review  of  GISTs  from  the  period
1990–2000 with supplementary immunohistochemistry.
Results: 31 cases were found, of which the first was registered in
1994,  the  majority  appearing  after  1997.  15  were  females,  16
males, aged 42–88 years with most patients older than 55 years. 13
cases were malignant, 5 of borderline malignancy and 13 benign.
One was a GANT, one presented as liver metastasis only, and a
patient  with  neurofibromatosis  had  multiple  benign  GISTs.14
tumors were located in the stomach, 9 in the small bowel, 1 in the
rectum and 6 in the abdomen. All tumors except one expressed
CD117 and 23 tumors CD34. 30 were vimentin, 5 actin, 2 desmin
and 25 bcl-2 positive. HMB45, CK, S-100 and CD99 were nega-
tive, NSE often inconclusive. EM, performed in 5 cases, revealed
no specialized cell type. Some 100 other mesenchymal gastrointes-
tinal  tumors  were  encountered, but  not yet reviewed. Of these
more than half were leiomyomatous, evenly distributed between
benign and malignant, the remainder a smaller number of fibrous,
neurogenic, histiocytic, vascular and un! classifiable benign/malig-
nant tumors.
Conclusion: Our material confirms the high frequency of CD117-
positivity, justifying GIST to be diagnosed as a separate entity,
thereby making possible a specific modality of postoperative treat-
ment. We intend to complete the study by collecting clinical infor-
mation, hoping to learn more about this tumor’s biology.
PET and  MRI co-registration  in pre-  and post treatment
evaluation of bone and soft tissue sarcoma.
H.W. HENDEL, A. EIGTVED, M. NOWAK, K.E. JENSEN, S.
DAUGAARD,  A.  KRARUP–HANSEN,  J.G.  PEDERSEN,  D.
HOVGAARD, L. DANBORG & B.H. PEDERSEN
(On behalf of the Sarcoma Group, Rigshospitalet, Copenhagen Univer-
sity Hospital, Denmark)
Purpose: Functional characterization of sarcomas by FDG-PET
can provide complementary information to MRI and CT. This
may prove useful in more accurate localization and evaluation of
the  tumour.  Due  to  the  heterogeneity  of  sarcomas,  PET/MRI
coregistration  could  provide  optimal  dataset  for  guidance  of
biopsy-procedures. Furthermore, image fusion with PET and MRI
can  provide  detailed  anatomical  localization  of  the  functional
changes in the tumour region.
Methods: Until  now, five patients with  primary sarcomas have
been included. Two have been reinvestigated after chemotherapy.
A  regional  FDG-PET  scanning  for  the  coregistration  was
performed with the extremity fixed in a mould, also used during
MRI. A surface-based fitting algorithm was used for coregistration
the PET transmission scan to the MRI data. The emission scan
was subsequently projected on the MR scan. From the PET data
we calculated the Standardized Uptake Value (SUV), representing
the degree of metabolic activity.
Results: PET  and  MRI  agreed  in  three  sarcomas  (synovial
sarcoma grade II, malignant peripheral nerve sheath tumour grade
III,  myxofibrosarcoma  grade  III)  regarding  morphology  and
metabolism.  Two  expressed  homogeneity,  one  heterogeneity.
However, in two heterogeneous sarcomas (high grade surface oste-
osarcoma,  high  grade  osteosarcoma),  MRI  indicated  a  larger
degree of tissue involvement than suggested by PET, probably due
to the difficulties in differentiating reactive tissue from malignant.
Post-treatment imaging revealed similar changes in tumour size.
PET showed decreased SUVs.
Discussion: PET/MRI  image  fusion  is  feasible  with  potential
advantages  compared  to  conventional  MRI  in  evaluation  of
sarcomas.
Core needle biopsy to avoid open biopsy for the diagnosis of
soft tissue masses (STM): a retrospective study.
I.  RAY-COQUARD,  H.  GHESQUIÈRES,  D.  RANCHÈRE-
VINCE,  P.  BIRON,  M.P.  SUNYACH,  M.  RIVOIRE,  T.
PHILIP, P. MÉEUS, C. SEBBAN, P. THIESSE & J.Y. BLAY.
(Centre Léon Bérard, Hopital Edouard Herriot, Lyon, France)
Open biopsy is considered as standard practice for the diagnosis of
soft-tissue sarcoma (STS). Core needle biopsy (CNB) is an alter-
native, with minimal morbidity and cost, but with a possible risk of
diagnostic inaccuracy. We conducted a retrospective study of the
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Method: All adult patients in whom a CNB was performed for
the  diagnosis  of  STM  between  1994  and  2000  were  selected.
Sensibility  (Se),  specificity  (Sp),  positive  (PPV)  and  negative
(NPV) predictive value were determined for the diagnosis of malig-
nancy (yes or no), connective tumor (i.e. benign or malignant),
sarcoma (STS), and lymphoma (NHL) by comparing CNB to the
gold standard histological, molecular or clinical diagnostic tests.
Total concordance was admitted when the CNB and gold standard
yielded similar diagnosis including subtype (e.g. liposarcoma), a
partial concordance was similar but without diagnosis of subtype
(e.g. STS). All other situations were considered as discordant.
Results: Among 110 CNB, 7 yielded insufficient tumor material
for diagnosis and 103 patients were analyzed. The final diagnosis
was  benign  tumor  (19%),  STS  (59%),  NHL  (7%),  aggressive
fibromatosis (5%), and carcinoma (6%). Hematoma was the only
reported side-effect of CNB (6%); Median size of biopsy speci-
mens was 19 mm (range 1–60). For all tumors, total concordance
was observed in 88% (91/103), partial concordance in 7% (8/103)
and discordance in 5% (5/103). Sp and PPV of CNB were 100%
for  the  diagnosis  of  malignancy,  STS,  NHL,  and  aggressive
fibromatosis. Se was 97% for the diagnosis of malignancy, 97% for
the  diagnosis  of  connective  tumor,  92%  for  the  diagnosis  of
sarcoma (100% for the diagnosis of high grade STS, 70% for the
diagnosis of low grade STS), 100% for the diagnosis of NHL. NPV
was 91% for the diagnosis of malignancy, 89% for the diagnosis of
connective tumor, 88% for the diagnosis of STS (100% for high
grade STS and 90% for low grade STS), and 100% for the diag-
nosis of NHL.
Conclusion: CNB enables to avoid open biopsy when a diagnosis
of  high  grade  STS,  lymphoma  or  aggressive  fibromatosis  is
obtained. CNB is less  accurate in benign connective tumors  or
low-grade STS.
The effect of changing diagnostical practices on the patho-
logical subclassification of soft tissue sarcomas
S. DAUGAARD
(Dept. of Pathology, Rigshospitalet, Copenhagen, Denmark)
Purpose: To  evaluate  the  effect  of  pathological  review  on  the
diagnostic subclassification of soft tissue sarcomas (STS).
Material and methods: Review of available archival pathological
material from patients with STS of the extremities, diagnosed in
the  years  1972–1995.  In  selected  cases,  immunohistochemistry
was performed.
Results: Overall, the review has so far led to a change in diagnosis
in 131  out  of  273  cases  (48%). Previously, the  most  common
subgroups  were  malignant  fibrous  histiocytoma  (MFH):  27%,
liposarcoma:  21%,  fibrosarcoma:  11%,  leiomyosarcoma:  11%,
and synovial sarcoma: 8%. Most were distributed fairly evenly over
time, but 65% of the MFHs were diagnosed in the 3rd quarter of
the period (1985–90). 84% of the fibrosarcomas and 73% of the
malignant fibrous histiocytomas were reclassified, compared with
only 19% of the synovial sarcomas, 18% of the liposarcomas, and
13% of the leiomyosarcomas. After review, the largest subgroup
became the liposarcomas (22%), leiomyosarcomas (19%), syno-
vial sarcomas (14%), MFHs incl. myxofibrosarcomas (10%), with
11% unclassified (NOS). Five benign lesions were identified: two
cases of nodular fasciitis, two lipomas (with degenerative changes),
and one  aneurysmal  fibrous  histiocytoma.  Among  the  fibrosar-
comas were five fibromatoses  (historically!  considered ‘fibrosar-
comas  grade_’).  New  entities  were:  two  cases  of  sclerosing
epithelioid fibrosarcoma and one low-grade fibromyxoid sarcoma.
Discussion: When using historical material, e.g. for the purpose of
evaluating possible prognostic factors or new molecular biological
diagnostic markers, pathological review following current diagnos-
tical  criteria  should  be  mandatory  in  order  to  avoid  statistical
contamination of the study population.
Pulmonary metastases from soft tissue sarcoma: an analysis
of prognostic factors with long-term follow-up
T.J. HIEKEN, C. SCHAEFFER & T.K. DAS GUPTA.
(Department of Surgical Oncology, University of Illinois at Chicago,
Chicago, IL, 60612, USA)
Soft tissue sarcomas frequently metastasise to the lung, which may
be  the  only site  of metastatic  disease.  A  proportion of affected
patients may experience long-term survival. We studied 119 soft
tissue sarcoma (STS) patients with lung metastases  (LM) in an
effort to identify factors associated with a favourable outcome. 54
female and 65 male patients, ranging in age from 18 to 83 years,
developed LM at a mean of 32 months (median 11 months) from
the time of initial diagnosis. Mean follow-up was 62 months for
surviving patients. Overall, 3-year survival was 18% and 23 of 119
patients  survived  <36  months  after  developing  LM.  From
numerous demographic and tumour features examined, only the
development of LM > 1 year after initial diagnosis (p = 0.002),
unilateral  versus bilateral  LM (p = 0.002),  resection  versus  no
surgical  treatment  (p<0.0001)  and  administration  of  chemo-
therapy  (p  =  0.03)  were  significant  variables.  The  latter  three
parameters retained significance in multivariate analysis. For the
subset of 48 patients who underwent metastectomy with curative
intent, 19 survived >36 months (actuarial 3-year survival 40%).
For this subgroup of patients, we identified the following markers
of poor prognosis: interval to LM <l 1 year, incomplete resection
and mutant p53 expression, assessed by quantitative ELISA assay,
by the metastatic tumour, suggesting that such tumours are biolog-
ically aggressive. These data confirm that long-term survival may
be achieved for a subset of patients with pulmonary STS metas-
tases,  predominantly  those  with  mutant  p53-negative  unilateral
metastases who undergo complete surgical metastasectomy.
Pulmonary metastases in soft tissue sarcoma
M.  PEIPER,  W.T.  KNOEFEL,  C.  BLOECHLE,  A.  HEI-
NECKE, E.G. ACHILLES & J.R IZBICKI
(Department of Surgery, University Hospital Hamburg, Germany)
Purpose: The lungs compromise a predilection site for pulmonary
soft tissue (STS) metastases.
Methods: A  retrospective  analysis  of  all  patients  operated  on
pulmonary  metastases  of  STS  between  1988  and  1999  was
performed. Patients and tumor characteristics as well as surgical
and pathological results were evaluated. RESULTS: 52 Patients
(31 female, 26 male) with a median age of 44 (18–75) years were
operated. Primary tumors were leiomyosarcomas (n = 13, 23%),
MFH (n = 10, 19%), malignant peripheral nerve sheath tumour
(n = 6, 13%) and 23 tumors of 11 other entities. 42% of patients
were  already  treated  with  primary  tumors  in  our  institution.
Primary  tumors  were  located  subcutaneously  in  12  patients,
subfascially in 25 patients and in 15 patients in parenchymatours
organs. 50% of primary tumors were poorly differentiated, while
30%  were moderate and 20%  were well  differentiated. 29%  of
primary tumors were resected achieving wide margins (R0), 81%
R1. In 12.5% of patients distant metastases were present at initial
diagnosis. In 40 patients, chemotherapy were administered (not in
randomized trials), 26 of these after diagnosis of pulmonary metas-
tases.  In  28  patients  local  recurrence  occurred,  in  25  of  these
before or simultanously with pulmonary metastases. Patients were
operated using thoracotomy or sternotomy, no patient was oper-
ated using thoracoscopy. Up to 4 operations and up to 38 pulmo-
nary tumors were resected. At the end of follow-up, 14 patients are
alive, while 38 died due to tumor disease. Mean survival time was
36.5 months and 19.5 months after metastasectomy. No signifi-
cant  statistical  parameters  were  found  associated  with  reduced
survival.
Conclusion: Though  most  patients  will  eventually  die  due  to
tumor disease, some  curations are noted and overall survival is176 EORTC Abstracts
better  than  in  most  other  malignant  diseases.  Even  recurrent
metastasectomy may be indicated in selected patients.
Tikhoff—linberg  operation  and  major  resections  of  the
shoulder girdle in sarcoma patients
M. PILER & J. NOVAK
(Department of Surgical Oncology, Institute of Oncology Ljubljana,
1000 Ljubljana, Slovenia)
Background and objectives: This study was undertaken to verify
the clinical results of limb-sparing Tikhoff-Linberg procedure and
major resections in patients with malignant bone and soft-tissue
sarcomas of the shoulder girdle treated at our Institute.
Patients and methods: From 1980 to 1999, 26 patients with malig-
nant bone and soft  tissue  sarcomas of the shoulder girdle  were
treated with a limb-sparing surgical procedure at the Department
of Surgical Oncology of the Institute of Oncology in Ljubljana.
Eighteen  patients  underwent Tikhoff-Linberg procedure, and 8
had major resection of the bone and soft tissue. Of 26 patients 14
were  females  and 12  males  with  the  age  range  14  to  71  years
(median 40 years). Sixteen patients had bone and 10 soft-tissue
sarcomas. Five patients had chemotherapy, 2 postoperative irradi-
ation and 3 patients chemotherapy and irradiation. The follow-up
period in limb-sparing group ranged from 4 months to 19 years 9
months (median 6 years 4 months).
Results: Fourteen patients (56%) are currently alive and desease-
free, with the follow-up from 1 year 3 months to 19 years (median
7 years 6 months); 2 died of other deseases, 9 died of sarcoma (4
of metastases and 5 of metastases and simultaneous local recur-
rence) at a mean (SD) interval of 15 months after surgery (range,
6–25 months). One patient was lost from follow-up 6 months after
surgery; he was not resident of Slovenia. Of 25 patients, 2 devel-
oped local recurrence without metastasis 6 months and 4 years 3
months after surgery (median 2 years 4 months). The bone was
reconstructed in 6 patients (prosthesis in 3, vascularised fibular
graft in 2, and intraoperative extracorporeal autogenous sterilised
bone graft in one). In 14 alive patients, hand-elbow function is
excellent in 7, good in 6, and fair in 1 patient.
Conclusion: Classical or modified Tikhoff-Linberg operation is a
suitable limb sparing procedure for tumors of the shoulder girdle.
A good hand-elbow function can be preserved with local recur-
rences  occuring  in  8  percent  in  this  as  well  as  in  majority  of
reported series.
Motor unit transplantation or transposition after compart-
mental excision of soft tissue sarcomas
R.  CAPANNA,  G.  BELTRAMI,  P.  CALDORA,  D.A.  CAM-
PANACCI, R. ANGELONI*, M. INNOCENTI*, G. LAURI* &
M. CERUSO*
(Department  of  Orthopedic  Oncology—*Center  of  Reconstructive
Microsurgery, C.T.O., Florenze, Italy)
Purpose: In order to obtain wide surgical margins in soft tissue
sarcomas of the limbs, the sacrifice of the entire muscle compart-
ment can be requested, with consequent function loss. After such
a case, a functional reconstruction can be done by a reinnervated
free muscle transplantation (motor unit transplantation) or by a
pedicled muscle transposition (motor unit transposition).
Subjects: From 1992 to 1999, 11 patients affected by soft tissue
sarcomas  (8  high  grade  and  3  low  grade),  after  compartment
muscle excision underwent reconstruction with motor unit trans-
plantation or transposition. All patients but 1 had been previously
treated by inadequate excision. In 6 cases the motor unit consisted
of a reinnervated free muscle (4 latissimus dorsi pro quadriceps, 1
latissimus d. pro extensor compartment of the leg and gracilis pro
extensor  compartment  of  the  forearm). The  remaining  5  cases
were pedicled muscle transpositions (latissimus d. pro deltoid).
Results: At a mean follow-up of 47 months (min 6; max 72), 8
patients showed a satisfactory functional results (MSTS); 1 had
major complication and failed postoperatively (vascular failure of
the free flap); 2 were rated as unsatisfactory (after postoperative
radiation therapy).
Discussion: Despite  the  difficult  surgical  technique,  after
compartment muscle defect, motor unit transplantation or trans-
position represents the only functional reconstruction. In case of
necessity  of  radiation  therapy,  preoperative  radiation  therapy
should be preferred for not impairing the flap’s viability.
Major  limb  amputation  in  the  treatment  of  extended
sarcomas of the extremities
T. STREICHERT, K.A. GAWAD, M. PEIPER, C. ZORNIG &
J.R. IZBICKI,
(Departments of Surgery, University Hospital Hamburg)
Objective: Curative resection of extended sarcomas of the prox-
imal extremities can often only be achieved by major amputations
due to infiltration of vital structures.
Material and Methods: 15 patients (10m:5f) with a mean age of
55  (25–81)  years  were  treated  by  either  exarticulation  of  the
shoulder (n = 3) or hip (n = 5), hemipelvectomy (n = 2) or inter-
scapulothoracic  amputation  (n  =  5).  2  patients  had  a  primary
manifestation  of  their  tumour,  all  others  had  recurrences.  The
primary  manifestation  was  25  (0–212)  months  before  and  the
patients had 3 (0–5) prior operations for the same disease. Cura-
tive resection (R0) was achieved in all cases. The majority of the
tumours were poorly differentiated (GII: n = 6, GIII: n = 9). The
hospital mortality was 6%, no major complications occurred.
Results: After a median follow-up (after the amputation) of 30
(2–108)  months 53% of the patients  were still  alive. 3 Patients
(20%) had died tumour related, 3 due to unrelated diseases and
one of unknown cause. The median survival time was 53 (2–321)
months after primary manifestation of the disease and 21 (2–108)
months  after  amputation.  One  patient  developed  pulmonary
metastases  5  months  after  hemipelvectomy,  one  patient,  now
disease free, developed local recurrence after exarticulation of the
shoulder and received R0 resection of the shoulder girdle stump.
All other patients were also free of recurrence or metastases.
Conclusion: Major  amputation  can  be  successful  even  in
extended, recurrent and poorly differentiated sarcomas.
Sciatic nerve resection: is that truly an indication for ampu-
tation?
Y. KOLLENDER, J. BICKELS & I. MELLER
(The National Unit of Orthopedic Oncology, Tel-Aviv Sourasky Med-
ical Center, Sackler Faculty of Medicine, Tel-Aviv  University,  Tel-
Aviv, Israel)
Background: En bloc resection of the sciatic nerve with a malig-
nant tumour of the pelvis or thigh was long considered an indica-
tion for an amputation because of the anticipated poor function.
The authors describe the functional outcome of a group of patients
who underwent a limb-sparing surgery in spite of the need to sacri-
fice the sciatic nerve.
Materials  and  Methods: Between  1991  and  1999,  the  authors
treated 12 patients who underwent limb-sparing  resections  of a
malignant tumour of the  thigh,  buttock, or pelvis,  all  of which
necessitated en bloc resection of a segment of the sciatic nerve withEORTC Abstracts 177
the  tumour  mass.  There  were  eight  females  and  four  males,
ranging in age from 2 to 73 (mean, 54 years).
Diagnoses: soft-tissue sarcomas—8, metastatic bone disease—3,
primary bone sarcomas—1.
Anatomic locations: thigh—7, pelvis—4, buttock—1. Follow-up
ranged from 10 to 102 months (mean, 30 months).
Results: At the most recent follow-up evaluation, eleven patients
were ambulatory and only one patient was wheel chair bound. Of
the ambulatory patients, only five patients required a walking aid
(crutches or a cane); a long-leg brace was not required by any of
these patients. Although all patients had an anesthetic ipsilateral
foot, none had a pressure sore or required a secondary amputation.
All ambulatory patients were satisfied with the functional outcome.
Conclusion: Provided the femoral nerve is intact, the mere neces-
sity to resect the sciatic nerve with a given tumor of the pelvis or
thigh is not an indication for an amputation.
Hyperthermic  isolated  limb  perfusion  with  TNF-a  and
melphalan in advanced soft tissue sarcomas: histolopatho-
logical considerations
Y.  KOLLENDER,  J.  ISSAKOV,  M.  GUTMAN.  LEV-
CHELOUCHE, S. ABU-ABID, K. MERIMSKY., J. BICKELS,
A.  NIRKIN,  G.  FLUSSER,  N.  MARUANI,  B.  LIFS-
CHITZ–MERCER., M. INBAR., J.M. KLAUSNER. & I. MEL-
LER
(The National Unit of Orthopedic Oncology. Department of Surgery B.
Sourasky Medical Center, Tel Aviv Israel)
Background, Materials and Methods: The specimens of 27 high
grade extensive soft tissue sarcomas (STS) and 3 desmoid tumours
of the extremities, after local treatment with hyperthermic isolated
limb perfusion (HILP) using TNF-a and Melphalan, were evalu-
ated for the type and extent of tumor necrosis and oilier histolog-
ical local tissue changes. Limb preservation was the objective in
this selected group of advanced STS’s, candidates for amputation
or  mutilating  surgery  otherwise.  The  tumoural  masses  were
obtained  6–8  weeks  after  HILP,  during  the  definitive  surgical
resection of the residual tumor according to protocol.
Results: Typical  histological  changes  were:  cystic  hemorrhagic
necrosis in the center of the remaining tumor with pericystic exten-
sive fibrosis. In 8 cases more than 90"/o necrosis was achieved. In
14  cases  the  percent  of  necrosis  was  between  60%  and  90%
(including 4 cases of 80–90"/o). In 8 cases less than 60% necrosis
was obtained. No correlation was found between these histological
responses and: the anatomical location of the tumor, whether the
tumor was primary or recurrent, the type of previous treatment
(systemic chemotherapy, radiotherapy) and it’s size. Some correla-
tion was found with: the histological type of tumor and with prox-
imal or distal location in the limb.
Conclusions: This is the First serial histological description of the
effect of high Dose TNF-a and Melphalan administered via HILP
on the tumoural masses of limb STS. The small number of speci-
mens and especially the variability of tumours precludes definitive
conclusions from the observed correlations. Larger numbers and
more homogeneity of the histologic types is needed in future series.
Beromun®  (TNF-A)  and  melphalan  for  limb  salvage  in
advanced limb neoplasms: A new standard of care for irre-
sectable soft tissue sarcomas
Y.  KOLLENDER*,  M.  GUTMAN**;  D.  LEV-
CHELOUCHE**,  J.M.  KLAUSNER**;  J.  ISAKOV*,  O.
MERIMSKY*; G. FLUSSER*, N. MAROUANI*; J. BICKELS*
& I. MELLER*
(*The National Unit of Orthopedic Oncology. **Department of Sur-
gery B. Sourasky Medical Center, Tel Aviv Israel)
Background: Beromun(B) (-rTNFa) is a highly potential antine-
oplastic  agent.  However,  since  its  systemic  administration  in
humans resulted in a life-threatening septic shock-like syndrome,
its use was abandoned
These  systemic  side  effects  were  eliminated  when  TNF  was
administered  via isolated  limb  perfusion (ILP). This  method is
now  being  used  in  order  to  prevent  amputation  ormutilating
surgery  in  patients  suffering  from  irresectable  limb  soft  tissue
sarcomas.
Methods: During a 7-year period, 70 pts with high grade STS
underwent  81  ILPs  with  high  dose  Berornun®  (3–4mg)  and
Melphalan (1–1.5mg/kg). There were 37 males and 33 females.
The mean age was 56 years (range 14–80 years).
.  31  pts  presented  with  recurrent  and  40  with  very  extensive
primary tumors. The tumors were located in the upper extremity
in 13 pts and in the lower extremity in 57 pts. All pts were candi-
dates for either amputation or extensive mutilating surgery. ILP
was  performed  via  the  corresponding  vessels  proximal  to  the
tumor. Resection of the residual tumor or tumor bed or limb was
performed 6–8 weeks after ILP, and all reported responses were
pathologically confirmed.
Results: Marked tumor softening occurred within 48 hours, and
in tumors protruding through the skin, hemorrhagic necrosis was
evident within 24 hours. The overall response rate was 80%. 21 pts
(30%) had a complete response and 40 (57%) had a PR. in 3 pts
(11%),  only  minimal  regression  was  observed  (stabilization  of
disease). Operative mortality was 3% (2 pts). Limb sparing was
achieved in 82% (62/70 pts). Amputation was performed in 8 pts.
Within a follow-up period of 2–76 months )median 24 m), 30 pts
(43%) are dead, 31 (44%) are alive with no evidence of disease
(median 49 m), and 9 (13%) are alive with disease. Local recur-
rence occurred in 16/60 evaluable pts (26%). Limb salvage and
survival  rates  were  not  significantly  different  for  gender,  age,
primary vs recurrent tumor, or tumor location.
Mortality was significantly higher for multifocal disease (73% vs
29%)(p<0.05). Limb salvage rates were also not different for the
various  histological  subtypes.  There  was  trend  towards  higher
response rates in synovial and clear cell sarcomas.
Conclusions: The  combination  of  Berornun®  and  Melphalan
given via ILP appears to be effective in pts with advanced STS
confined to the limb, achieving a high response rate and limb pres-
ervation.
Primary radicalization plus radiotherapy after inadequate
surgery in soft tissue sarcomas
G.  BELTRAMI,  R.  CAPANNA,  P.  CALDORA,  D.A.  CAM-
PANACCI, A. FRANCHI* & M. PERTICI**
(Department of Orthopedic Oncology, CTO, Florenze; *Department of
Pathology, Florenze **Department of Radiotherapy, Florenze)
Purpose: After  inadequate  margins  in  Soft  Tissue  Sarcoma
(STS),  there  is  no  general  agreement  about  further  treatment
(surgery and or radiotherapy). This is particularly evident with no
evidence of clinical or radiological disease. We report our experi-
ence, comparing two groups of patients: one, primarily observed in
our Center (group A), and one inadequately operated elsewhere
(group B). Both groups underwent surgery, and, when feasible,
brachytherapy and external radiation therapy.
Subjects: From 1987 to 1999, 241 patients affected by STS of
limbs have been treated in our Center: 68 where first observations
(group A), 75 where primary radicalizations (group B). Ninety-
eight have been excluded since affected by local recurrence (oper-
ated elsewhere) or amputated. High grade STS were represented
in 68% of group A and 80% of group B while a location distal to
knee or elbow was in 35% of group A and 63% of group B.178 EORTC Abstracts
The average time of radicalization after the previous surgery was
three months and viable tumoural cells were found in 45% of spec-
imens of group B.
Free or rotational flaps, for covering the loss of substance, were
performed in 20% of group A and in 44% of group B.
Brachytherapy was applied in 63% of group A and in 57% of group
B, while conventional radiation therapy was performed in 79% of
group A and 67% of group B.
Results: At  an  average  F.U.  of  54  months  (5–150),  76%  of
patients were continuous disease free in both groups. Local recur-
rence occurred in 3% of group A and in 5% of group B. In group
B, as far as the local recurrence rate is concerned, 6% appeared in
positive  specimens  and  5%  in  negative  specimens.  Functional
results (MSTS) were rated as satisfactory in 80% of group A and
88% of group B.
Discussion: After  inadequate  surgery  of  STS,  surgical  reprises
associated to adjuvant radiation therapy showed to be efficacy in
local control, even in distal location, although with high percentage
of free flaps, not impairing the functional results.
Is adjuvant radiation (RT) indicated after optimal resection
for soft tissue sarcoma (STS) of the extremities?
A. LE CESNE, K. KHANFIR, P. TERRIER, C. ALZIEU,  BON-
VALOT, D. VANEL, T. TURSZ & C. LE PECHOUX
(Institut Gustave Roussy, Villejuif, France)
The impact of adjuvant RT on both local control and distant relapse
is not clearly established after wide excision of extremity STS.
Purpose: We performed a retrospective analysis on behavior of
patients  (pts)  who underwent a  large  resection  (first  or second
resection) in our institution and received or not adjuvant RT: All
histological specimens were carefully analyzed and only pts with
free tumoral margins (ftm) were retained for analysis. Histopatho-
logical classification was as following: minimal R0 (mR0) resection
(ftm<10mm) and optimal R0 (oR0) resection (ftm >10 mm).
Patients: from 1975 to 1996, 133 pts with a median age of 44 yrs
were operated at IGR. The median tumor size was 6cm. Ninety-
three pts (70%) primary resected in other centers, were reoperated
and residual tumor cells (RTC) were found in 54% of pts. Sixty-
nine pts (17 oR0 and 52 mR0) received adjuvant RT and 64 pts
did not (54 oR0 and 10 mR0). Characteristics of pts were similar
in both groups.
Results: Median follow-up time was 1o yrs (3 or 25). Thirty-three
pts had a local relapse: 11 in the RT group and 22 pts in the control
group (p 0.01). Grade and ftm are correlated to OS and adjuvant
RT to RFS. A positive impact of RT on local control was only seen
in pts with a mR0 resection (p = 0.005) and in pts with RTC after
reexcision (p = 0.001). RT has no influence on 5 and 10 yr-OS.
Conclusion: optimal  resection  seems  to  be  the  best  predictive
parameter for a favorable outcome in term of local control in local-
ized STS. Adjuvant RT is indicated in mR0 resections and in case
of RTC after definitive surgery, but its role after oR0 resection has
to be validated by a prospective randomized trial.
Local control after external beam radiation therapy (EBRT)
and  intraoperative  brachytherapy  (BT)  in  soft  tissue
sarcomas (STS).
G. SCARZELLO, *C.R. ROSSI, R. MAZZAROTTO, A. RIG-
ON, M.S. BUZZACCARINI, *M. FOLETTO, *P. PILATI, **A.
DAL PALÙ, **F. MICHIELAN & G. SOTTI.
(Dept. of Radiation therapy, *Dept of Surgical and Oncologic Sciences,
**Dept of Anestesiology Azienda Ospedale Università, Padova, Italy)
Since 1988 we have been collecting data regarding pts. with histo-
logically  proven  diagnosis  of  STS,  treated  with  conservative
surgery and EBRT plus intraoperative BT, in order to assess local
control and late effects. In our files were registered 64 pts. with
primary  localization  as  follows:  54  extremities,  3  head-neck,  3
trunck-abdomen, 4 genito-urinary system. All pts. underwent BT
with intraoperative implant up to a total dose of 15–25 Gy. 7 of
them  previously  received  40–50  Gy  of  preoperative  EBRT,  57
received EBRT roughly a week after BT. 4 had hyperthermic anti-
blastic intraartherial perfusion before operation. 5 paediatric pts.
were treated only with BT. No one had considerable radiotherapy
related acute toxicity. At a median follow-up of 4 years, we regis-
tered a local relapse free survival of 95.3%. No severe late effects
are observed at this dose of BT. BT allows to give RT avoiding side
effects related to external beams, moreover it reduces the time for
the local treatment, anticipating chemotherapy if required.
Neoadjuvant concurrent chemoradiotherapy and extremity
preserving surgery in the soft tissue sarcomas of the extrem-
ities
Y. ANACAK1, Z. ÖZSARAN1, D. SABAH2, T. AKALN3, A.
MEMI4, A. HAYDAROLU1, G. YÜCETÜRK2, R. ARKUN4 &
G. KANDILO_LU3
(Ege University  Medical  School  1Radiation  Oncology,  2Orthopedics
and traumatology, 3Pathology, 4Radiodiagnostics–Izmir–Turkey)
Purpose: This phase-II study was designed to assess the role of
neoadjuvant chemoradiotherapy and extremity preserving surgery
on the local control and survival of the patients having extremity
soft tissue sarcomas. The histological response of the tumors to the
neoadjuvant therapy was also assessed.
Patients: Between 1994  September—2000  May 68  cases  were
included to the study having the median age 44 (17–77). M/F ratio
was 1.7. The diagnosis was done with tru-cut biopsy; the most
common subtype was liposarcoma.
Methods: All cases were treated with 50.4 Gy (2Gy/day, 5 frac-
tions/week) and 3 cycles of concurrent chemotherapy (mitomycin
8mg/m2,  doxorubicin  40mg/m2,  cisplatinum  60  mg/m2).  One
month after  the  end of neoadjuvant therapy wide  excision  was
performed in 52 cases and amputation in 2 cases. 14 patients were
not operated due to refusal of operation or metastatic outcome.
2–3 cycles of additional chemotherapy was given in 11 cases.
Results: After  a  median  follow-up  of  27  months  (3–74),  local
recurrence was developed in 4, lymph node metastasis in one and
distant metastasis in 21. Local recurrence free survival was 88.8%
and distant metastasis free survival was 49.1% at 3 years. 17 cases
were lost  due to tumor progression; cause specific  survival was
51.9% at 3 years.
Discussion: Concurrent neoadjuvant chemoradiotherapy in soft
tissue sarcomas is feasible. Further randomized studies are needed
to clarify the role of neoadjuvant radiochemotherapy on the local
control and survival of soft tissue sarcomas.
Re-excision  of  retroperitoneal  sarcoma  after  inadequate
initial surgery
A. CALVACANTI*‡, A. LE CESNE*, C. LEPECHOUX*, P.
TERRIER*, D. VANEL* & S. BONVALOT*‡
(Department of Surgical Oncology‡, Sarcoma Unit* Institut Gustave-
Roussy Rue Camille Desmoulins. Villejuif France)
Re excision of limb’s sarcoma after inadequate surgery finds 45 to
50% residual tumour cells.
The objective of this study is to determine the prevalence of residual
tumour after marginal excision of retroperitoneal sarcoma (RPS).
Patients with residual mass on imaging or described by the medical
report were excluded.EORTC Abstracts 179
Among  the  94  retroperitoneal  sarcoma  operated  at  Institut
Gustave-Roussy between November 1997  and November 2000,
ten underwent systematic re-excision. Initial surgery was in these
cases  marginal  excision  of  the  RPS  with  4  effractions  of  the
tumour. Median age of the patients was 41 years. FNLCC grade
were grade 1 n = 4, grade 2 n = 3, grade 3 n = 3. ’En bloc’ resection
of  the  initial  surgical  area  was  performed  with  5  colectomy,  6
muscle’s  resections,  1  posterior  pelvectomy,  1  omentectomy,  1
duodeno-pancreatectomy, 1 nerve’s excision.
Results: Residual tumour was found in 7 patients (70%). Macro-
scopically obvious n = 3 (with 2 sarcomatosis) and microscopically
n = 4. Surgical margins when residual tumour was found were R0
n = 4, R1 n = 3 (2 sarcomatosis) (UICC R classification). Postop-
erative treatments were: intra peritoneal chemotherapy n = 2, radi-
otherapy n = 3, chemotherapy n = 1.
With a median follow up of 20 months, 4 recurrences occurred; the
two patients with sarcomatosis and 2 patients with initial tumour’s
effraction but with no residual tumour found at re-excision. One
recurrence was both local and metastatic.
Conclusions: As limb’s sarcoma, marginal excision and effraction
of retroperitoneal sarcoma are prohibited. Surgery must be << en
bloc >> with adjacent organs*. Marginal excision of RPS leads to
high rates of residual tumours (70%) and re excision after inade-
quate surgery must be discussed.
*Surgical  management  of  primary  and  recurrent  soft  tissue
sarcoma of the retroperitoneum ASCO Proceedings, 1997, 1807.
Bonvalot S, Dube P, Le Cesne A Terrier P, Vanel D, Genin J.
Peritoneal  hyperthermic  perfusion  after  cytoreductive
surgery  in  patients  with  retroperitoneal  sarcomas  and
GISTS
M. FOLETTO, C.R. ROSSI, P.L. PILATI, M. DE SIMONE, M.
DERACO AND M. LISE
(Clinica Chirurgica, University of Padua, Italy)
Purpose: Retroperitoneal sarcomas and GISTS are usually a chal-
lenging  therapeutical  issue,  with  high  recurrence  rates.  The
purpose of this work was to evaluate, within a phase 1 study, the
feasibility  of  cytoreductive  surgery  (CS)  in  combination  with
hyperthermic intraperitoneal intraoperative chemotherapy (HIIC)
with doxorubicin and cisplatin.
Patients and methods: 18 out of 32 enrolled patients had recurrent
or  multiple  retroperitoneal  sarcomas/GISTS  underwent  HIIC
with doxorubicin and cisplatin at escalating dose (5–19 mg/l and
20–43  mg/l,  respectively),  after  CS  (tumor  residues  <  3  mm).
Loco-regional toxicity was evaluated according to modified Ozols’
criteria  while  systemic  according  to  WHO  criteria.  Follow-up
controls were scheduled monthly for the first 3 months, then every
three months until 18th month and then every six months.
Results: Post-operative complications occurred in 4 patients (2
septic  shock,  1  fistula  and  1  pneumothorax).  Loco-regional
toxicity was grade 1 in 5 patients, grade 2 in 3 and grade 4 in one
that required re-operation for adhesiolysis after 20 days. Grade 1
hematological toxicity was reported in 3 patients, while persistent
fever in another 3. After a median follow up of 24 months (range
12–36), 9 patients are NED (50%), 6 (33%) are AWD, 2 (11%)
DOC and 1(5%) die of tumor progression. 7(39%) patients devel-
oped local recurrence and 3 of them had re-do HIIC.
Conclusions: HIIC in combination with CS is feasible and seems
to improve local disease control in this  subset of patients,  with
acceptable  toxicity  and  morbidity.  Large  series  is  needed  to
confirm these results.
Preoperative chemotherapy for myxoid liposarcoma
S. KURATSU, N. ARAKI, A. MYOUI, T. UEDA, N. TAMAI,
S. JOYAMA & H. YOSHIKAWA
(Department  of  Orthopaedic  Surgery,  Kure  National  Hospital  3–1
Aoyamacho, Kure-city, Hiroshima 737–0023, JAPAN)
Purpose: Myxoid  liposarcoma(ML)  has  been  classified  as  an
intermediate grade tumor with a definite metastatic potential. But
little is known about its sensitivity to chemotherapy. The current
study reports on the clinical results and evaluates the efficacy of
preoperative chemotherapy.
Patients and Methods: We reviewed our experience in 26 cases of
ML treated at Osaka University Hospital and two affiliated hospi-
tals  from  1982  to  1997.  The  median  follow-up  was  63
months(range, 10–207).
Results  and  Discussion: There  were  13  male  and  13  female
patients with age range from 19 to 72 years(median:46). The most
common lesion was the thigh(62%). The median size of primary
tumor was 10 cm in maximum dimension. Of 23 cases treated with
chemotherapy, 13 cases were received doxorubicin-, cisplatin-, and
ifosfamide-based chemotherapy(mean, 2 cycles) preoperatively. In
13 cases, 10 cases were evaluable for response(6 partial response,
4 no change). The surgery had intralesional or marginal excision in
1, contaminated wide (almost wide and partially marginal) excision
in 5, and wide excision in 4. Among the 10 cases, 1 that underwent
intralesional excision because of large tumor recurred and metas-
tasised. At the last follow-up, 9 patients were alive with no evidence
of disease, and 1  with local recurrence had died due to a lung
metastasis. All of 8 cases underwent initially marginal excision only
at  the  other  hospitals  recurred  locally  and  subsequently  were
treated at our hospitals, whereas none had recurred and metasta-
sised  in 5  cases  received preoperative chemotherapy in spite  of
contaminated wide excision. ML is usually intra or intermuscular,
and is often large and bulky. Local recurrence is more common if
inadequate(intralesional or marginal) excision has been performed.
Therefore ML adjacent to bone, neurovascular structures is diffi-
cult to control locally by surgery only. We conclude that preoper-
ative chemotherapy should be considered for patients with large,
bulky myxoid liposarcoma in the neoadjuvant setting so as to mini-
mize the morbidity of radical local therapy in responding patients.
Orthoptic heart (ht) and heart-lung (hlt) transplantation for
unresectable primary cardiac sarcomas (pcs).
S.  TALBOT1,  M.L.  KEOHAN1,  L.  SCHULMAN2,  N.
EDWARDS3,  M.  GALANTOWICZ3,  M.  OZ3,  R.E.
MICHLER3, M. GINSBURG3 & R. TAUB3
(1. Divisions  of Medical Oncology1, Medicine2, and  Cardiothoracic
Surgery3, College of Physicians  and Surgeons, Columbia University,
New York, NY)
Purpose: The prognosis for patients (pts) with primary cardiac
sarcomas (PCS) is poor, especially when surgical extirpation is not
feasible.  The  median  survival  (MS)  is  generally  <10  months.
Removal of all cardiopulmonary structures involved by tumour,
followed by orthotopic HT or HLT has been attempted to improve
long-term  survival. Patients: From 1993–1999, we performed 4
heart and 4 combined heart and lung resection followed by HT or
HLT in 8 pts (3 men, 5 women).
Results: Median age at diagnosis was 43 years (range 37–64). Of
8 pts, 6 were given doxorubicin-based chemotherapy prior to HT/
HLT. Median follow up is 43 months (m) (range 5–67). Median
time from diagnosis to transplantation is 7 m (range 2–25). All but
2  HT  patients  developed  metastatic  disease  progression  (DP).
Median time to DP from diagnosis was 31 (range 28–35) and 12
m (range 10–40), and from transplantation 24 (range 20–29) and
5 m (range 0–34) for HT and HLT pts respectively. Six pts died:
3 HT and 3 HLT pts. MS from diagnosis was 53 (range 4–92+)
and 39 m (range 11–57+), and from transplant were 45 (range
2–67+) and 31 m (range 5–49) for HT and HLT pts respectively.
One HT pt died suddenly 3 m after transplantation without clin-
ical evidence of disease, and 1 HLT pt died 5 m post transplant of180 EORTC Abstracts
respiratory failure after a complicated post operative course but
had DP. Two pts remain alive: 1 HLT pt 47 m post POD with
cerebral metastases as the only site of recurrence!, and 1 HT pt free
of disease 67 m post transplant.
Discussion: Orthoptic HT or HLT is a technically feasible treat-
ment  for highly selected  pts with  localized advanced PCS. The
high incidence of metastatic disease may limit the usefulness of HT
or HLT.
Use of valspodar and Doxorubicin for the treatment of P-
glycoprotein positive sarcomas.
E. CAGLIERO, N. BALDINI, S. BRETTI & R. FERRACINI
(I.R.C.C, Candiolo (TO), Italy)
Chemotherapy resistance of cancer cells is the major limitation to
this  treatment  approach. Multidrug resistance  (MDR) in many
human cancers may be due to the  expression  of the  multidrug
transport P-glycoprotein (Pgp). New drugs developed specifically
to  inhibit  Pgp,  such  as  Valspodar  (PSC  833—Novartis),  may
provide  clinicians  with  more  potent  and  specific  inhibitors  for
MDR modulation trials.
We have investigated the cytotoxic effect of doxorubicin (DXR)
combined with PSC 833 on cultured human sarcoma cell lines (U-
2 OS, U-2/neo8, U-2 OS/DX580, OS/DX35, OS/DX117.1, OS/
DX117.2), expressing various levels of Pgp. The major cytotoxic
effects were achieved through the continuous presence of PSC 833
in the medium, therefore showing that sustained effective concen-
tration of PSC 833 during DXR administration is needed in order
to obtain maximal effect.
We have furthermore evaluated Pgp expression in sporadic canine
osteosarcoma,  confirming  its  high  incidence.  These  data  let  us
develop a novel protocol for the treatment of canine osteosarcoma
using PSC 833 and DXR. We have evaluated the pharmacokinetic,
toxicity and side effects of this combined treatment that resulted
active and well tolerated.
Our  studies,  considered  with  the  previous  literature,  support  a
rational to develop a risk-adapted strategy in human patients with
Pgp positive  cancer at clinical onset that  could be treated with
combined regimes including DXR and PSC 833, in order to revert
multidrug  resistance.  Since  soft  tissue  sarcomas  are  shown  to
express  MDR  phenotype  in  a  high  percentage  of  cases,  while
present chemotherapeutic treatments of these tumours need major
improvements,  we  therefore  propose  to  develop  a  clinical  trial
using DXR in association with PSC 833 in sarcoma patients whose
primary tumours were shown to express detectable levels of Pgp.
Prognostic value of microvessel density, proliferation and
apoptosis in liposarcoma
E.G.  ACHILLES*,  S.  LASCH*,  J.  SCHULZ*,  J.  SCHULTE
A.M. ESCH*, M. PEIPERo, W.D. BEECKEN+, O. KISKER‡,
X. ROGIERS* & J.R. IZBICKIº
(From the Departments of ºGeneral and *Hepatobiliary Surgery, Uni-
versity  Hospital  Hamburg,  Hamburg,  and  the  +Clinic  for  Urology,
University Hospital Frankfurt/Main, Frankfurt, and the ‡Department
of General Surgery, Philipps University Marburg, Marburg Germany)
Purpose: As an adjunct to conventional grading in human liposa-
rcomas, the possible prognostic value of intratumoural microvessel
density, rate of tumour cell apoptosis and proliferation was inves-
tigated.
Patients and Methods: 51 patients (female n = 21, male n = 30)
with liposarcoma resected between 1988 and 2000 in our center
were included in this study. Tumours were localised in the extrem-
ities  (n  =  28),  retroperitoneum  (n  =  20)  and  trunk  (n  =  3).
Tumour margins were free (n = 25) or showed residual micro-
scopic (n = 25) or macroscopic (n = 1) disease. Multiple variables
for  each  patient,  including  age,  sex,  tumour  size,  grading  and
numbers  of  microvessels,  apoptosis  and proliferating  cells  were
determined. Immunocytochemistry was performed for semiquan-
titative  analysis  of  representative  paraffin  embedded  tissue
sections.  Monoclonal antibodies  targeted  to  platelet/endothelial
adhesion molecule (CD-31), proliferating cell nuclear antigen and
apoptotic  nuclei  (Tunel-assay)  were  utilised.  The  results  were
correlated with the postoperative course of these patients.
Results: The median survival time was 10.2 years. Multivariate
analysis  (Cox—regression)  revealed  no  significant  correlation
between survival and all variables tested.
Discussion: These data indicate that in liposarcoma—contrary to
carcinoma—microvessel density, tumour cell apoptosis and prolif-
eration  are  of  no  prognostic  value  in  the  assessment  of
disease—specific  survival.  Further  studies  are  currently  under-
taken to determine the prognostic potential of these variables in a
larger series including other types of soft tissue sarcoma.
C-reactive protein levels in patients with malignant fibrous
histiocytomas
H.  NAKANISHI1,  N.  ARAKI1,  I.  KUDAWARA2,  A.
MATSUMINE2, M. MANO3, T. UEDA4 & H. YOSHIKAWA1
(1Department of Orthopedic Surgery, Osaka Medical Center for Cancer
and Cardiovascular Diseases, 2Department of Orthopedic Surgery, Na-
tional  Osaka  Hospital,  3Department  of  Pathology,  Osaka  Medical
Center for Cancer and Cardiovascular)
Paraneoplastic syndrome, for example, anorexia, weight loss, leuke-
moid reaction, frequently occurs in some advanced cancer patients.
However, these phenomena in mesenchymal tumor patients are
relatively  uncommon except  for malignant fibrous  histiocytoma
(MFH). Since there has been no report concerning the incidence
and clinicopathological characteristics of paraneoplastic syndrome
in MFH, we measured the serum C-reactive protein (CRP) concen-
tration in MFH patients continually from the first admission, and
analyzed its correlation with the clinicopathologic features.
Methods: Thirty patients (male/female; 12/18) with primary soft-
tissue MFH were studied, who underwent radical surgery between
May 1988  and Dec 2000.  The mean age was 59  years (range;
43–85). The correlation between the serum CRP levels and the clin-
icopathologic features (size, depth, grade, metastasis) was analyzed.
Results: In twenty-one patients  (70%), the  preoperative serum
CRP level was elevated. The histologic type was predominantly
striform-pleomorphic type (19 cases; 90%). In 19 cases (90%) out
of the elevated CRP cases, paraneoplastic syndrome such as fever,
leukocytosis, anemia, hypoalbuminemia, and hepatic dysfunction
developed. When the tumor was removed, the elevated CRP levels
subsided into the normal range in all cases. Tumor size and depth
were  significantly  different  between  two  groups  (p<<0.05,
p<<0.001, respectively), but not in histological grade and pulmo-
nary metastasis rate. In 2 cases out of 3 relapsed cases, the serum
CRP level re-elevated with the tumor regrowth.
Discussion: Paraneoplastic syndrome was not an unusual event in
MFH, especially in the cases with an elevated serum CRP level.
Serum CRP level may be a useful indicator of the disease status
and a new tumor marker to detect the relapse of MFH.
Multidrug resistance in soft tissue sarcomas: downregula-
tion of P-glycoprotein during metastatic progression.
R. KOMDEUR, W.M. MOLENAAR, N. ZWART, H.J. HOEK-
STRA, E.V.D. BERG, W.T.A.V.D. GRAAF
(Groningen University Hospital, Groningen, The Netherlands)EORTC Abstracts 181
Metastatic soft tissue sarcomas (STS) have a response rate of only
20–30%  to  standard  chemotherapy  (doxorubicin,  ifosfamide),
possibly due to the so-called multidrug resistance (MDR). MDR is
associated  with  the  over-expression  of  P-glycoprotein  (P-gp),
Multidrug  Resistance-associated  Protein  1  (MRP1)  and  Lung
Resistance-related Protein (LRP). Since it is unknown if metastatic
STS are more resistant than their primary counterparts, we studied
the MDR-status in paired samples. Samples from 33 chemonaive
primary STS and their metastases were collected; 85% of the metas-
tases was unexposed to chemotherapy. Expression  was assessed
immunohistochemically, using monoclonals C494 (P-gp; Signet
Lab), MRPr1 (MRP1; Dr Scheper, Free University Amsterdam)
and LRP (LRP; Transduction Lab). Expression was scored as posi-
tive (>5% positive tumor cells) or negative. P-gp expression was
positive in 29/32 primaries (91%), versus 22/30 metastases (73%);
paired analysis revealed significantly fewer P-gp positive metastases:
P<0.05. MRP1 was positive in 17/30 primaries (57%), versus 19/30
metastases  (64%). LRP was positive in 25/32 primaries (78%),
versus 26/32 metastases (81%). MRP1 and LRP expression did not
significantly differ between primaries and metastases. In conclu-
sion, this selective group (all metastasised) revealed a high expres-
sion  of  P-gp,  MRP1  and  LRP  in  the  primaries.  Remarkably,
significantly less metastases were P-gp positive (P<0.05). MRP1
and LRP expression in the primaries did not differ from the metas-
tases in this group. These results suggest that metastatic progression
does not coincide with upregulation of MDR status in STS.
GP170,  bcl2,  MIB1  and  TopoII  expression  in  abdominal
leiomyosarcoma (ALS) and in round cells sarcoma (RCS).
Correlation  with  biological  characteristics,  grading  and
response to chemotherapy (CT).
A.  COMANDONE*,  A.  BOGLIONE*,  E.  BERARDEN-
GO#MC, R. BUSSONE", A. BERNARDI#MC, O. DAL CAN-
TON*, C. OLIVA* & P. BERGNOLO*
(*Medical Oncology, Ospedale Gradenigo, #mCDivision of Pathology
and "Surgery, Ospedale SanGiovanni, Torino, Italy)
ALS  account for  5%  of soft  tissue  sarcomas  (STS). These are
tumours of adult-aged life, more common in women than in men.
CT is scarcely active. On the contrary RCS is typical for children
under 15, more common in men than women. We compared the
expression of GP170, bcl2, MIB1 and TopoII in 23 ALS and 18
RCS  paraffin-embedded  samples.  Results  ALS:  MIB1+  56%,
TopoII+ 34%, with a significant correlation (p = 0.03) to histology.
The same  markers weren’t correlate to grade, bcl2 and GP170
activity. Moreover no correlation to ADM therapy and response was
seen in 11/23 pts treated with CT. RCS: all but three were G3
tumours (83%). MIB1 was positive in 100% and TopoII in 94%
of the cases (p<0.001 to histology). No correlation with TopoII/
grade, GP170/histology and bcl2/histology and grade was seen. Only
6/18 pts received CT and statistical considerations cannot be done.
In  conclusions  Immunohistochemically  detection  of  proliferate
indexes (MIB1 and TopoII) may add some important information
in the prognostic criteria either in ALS or in RCS. Less defined is the
role of GP170, bcl2, MIB1 and TopoII to predict response to CT.
Lung  resistance-related  protein  expression  in  rhabdomy-
osarcomas in children versus adults
J.W.  KLUNDER1;  R.  KOMDEUR2;  W.T.A.  VAN  DER
GRAAF2; H.J. HOEKSTRA3; E. VAN DEN BERG4 & W.M.
MOLENAAR1
(Depts. of Pathol.1, Int. Med.2, Surg.3 and Med. Genet.4, Univ. of
Groningen, Groningen, The Netherlands)
Purpose: The prognosis of patients with a rhabdomyosarcoma,
treated with chemotherapy, seems better in children compared to
adults. This could be due to overexpression of Lung Resistance-
related Protein (LRP).
Material and methods: Primary, chemonaive rhabdomyosarcomas
of 24 children (24 embryonal, including 2 botryoid) and 15 adults
(9 embryonal, 3 alveolar and 3 pleomorphic) were assessed immu-
nohistochemically using an LRP antibody (Transduction Labora-
tories, Los Angeles, CA). Patients were considered adult when the
age at diagnosis was 16 years or higher, the samples were consid-
ered positive if >5% of the tumor cells was immunoreactive.
Results: Although not significant (p<0,1), adults were found to
have a higher expression of LRP, i.e. 73% of the tumours from
adults and 46% of those from the children. LRP immunoreactivity
was especially prominent in better differentiated cells. Among the
embryonal tumours 7 of 9 (78%) tumours from adults were posi-
tive as compared to 11 of the 24 (46%) in children. All three pleo-
morphic  and  1  of  3  alveolar  tumours,  i.e.  types  of
rhabdomyosarcoma with a poorer prognosis, were positive.
Discussion: There is a difference in LRP expression in rhabdomy-
osarcomas between adults and children. Whether this may explain
the  worse  outcome  of  adults  with  rhabdomyosarcomas  as
compared to children needs further investigation.
Multidrug resistance protein expression in rhabdomyosar-
comas before and after chemotherapy
W.M. MOLENAAR1, J.W. KLUNDER1; R. KOMDEUR2; H.J.
HOEKSTRA3 & V.D.E. BERG4; W.T.A. VAN DER GRAAF2
(Depts. of Pathol.1, Int. Med.2, Surg.3 and Med. Genet.4, Univ. of
Groningen, Groningen, The Netherlands)
Purpose: Rhabdomyosarcomas  generally  respond  fairly  well  to
chemotherapy.  The  residual  lesions  often  show  morphologic
differentiation,  presumably  caused  by  selective  insensitivity  of
differentiated tumor cells to chemotherapy. Insensitivity may be
related to multidrug resistance, associated with overexpression of
P-glycoprotein (P-gp), Multidrug Resistance  Protein 1 (MRP1)
and Lung  Resistance  Protein  (LRP). Therefore, pairs  of  rhab-
domyosarcomas before and after chemotherapy were compared.
Material: Tissue of 10 primary rhabdomyosarcomas from 5 adult
and 5 pediatric patients and of 8 corresponding residual tumours
and 2 metastases was assessed immunohistochemically for P-gp,
MRP and LRP. The samples were scored semiquantitatively.
Results: All specimens after chemotherapy showed clear differen-
tiation  as  compared  to  their  primaries.  All  except  one  primary
tumours expressed P-gp and all but three MRP. LRP was much
less extensive and absent or less than 5% in 4 cases. In all but one
case  each,  P-gp  and  MRP  expression  after  chemotherapy  was
similar  or  even  less  than  before.  In  contrast,  LRP  (strongly)
increased  after  chemotherapy  in  7  cases.  Moreover,  both  in
primary and residual tumours, LRP expression was most promi-
nent in the most differentiated tumor cells.
Discussion: The  morphologic  differentiation  of  rhabdomyosar-
comas  under the  influence  of  chemotherapy  may  be related  to
selection of LRP expressing, differentiated tumor cells.
Detection of SYT-SSX fusion gene in peripheral blood from
a patient with synovial sarcoma
A.  MYOUI,  N.  HASHIMOTO,  N.  ARAKI,  T.  ASAI,  H.
SONOBE, S. HIROTA & H. YOSHIKAWA
(Department of Orthopedic Surgery, Osaka University Medical School,
2–2 Yamada-oka, Suita 565–0871, JAPAN)
Purpose: Recent molecular analyses revealed that a specific trans-
location, t(X;18)(p11.2;q11.2) in synovial sarcoma (SS) induces a
fusion gene, SYT-SSX. The purpose of this study is to establish
the sensitive method to detect circulating SS cells by RT-PCR.182 EORTC Abstracts
Patient: A 22-year-old woman with poorly-differentiated SS in
the  right  thigh  was presented to  our hospital.  She  was initially
treated with wide excision of the tumor alone because she was in
27th week of pregnancy when the diagnosis was made. However,
multiple lung metastases developed six weeks after primary tumor
excision, and intensive chemotherapy was given after delivery.
Methods: Peripheral blood samples  were drawn before  biopsy,
two  months  after  primary  tumor  excision  when  multiple  lung
metastases were apparent on chest X-rays, and after first cycle of
chemotherapy.  mRNA  was  extracted  from  the  blood  samples.
After  RT-PCR  with  a  primer  set  that  is  specific  for  SYT-SSX
fusion gene transcripts, the PCR product was subjected to nested
PCR with second set of primers that yields 212-bp product from
the first 585-bp PCR product.
Results and discussions: The SYT-SSX fusion gene transcript was
detected by nested PCR in the peripheral blood collected prior to
biopsy, but not after the primary tumor excision. Six weeks after
the tumor resection, multiple lung metastases developed. This is
the first reported case in which tumor cells were detected by nested
PCR in the peripheral blood of a SS patient, and it is suggested that
monitoring of the circulating tumor cells may be a prognostic indi-
cator for SS patients.
C-erbB-4 expression in limb STS: correlation with neoadju-
vant chemotherapy results.
O. MERIMSKY, J. ISSAKOV, J. BICKELS, Y. KOLLENDER,
G. FLUSSER, S. VJACHESLAV, I. SCHWARTZ, M. INBAR &
I. MELLER
(O. Merimsky, MD, Dept. of Oncology, The Tel-Aviv Sourasky Med-
ical Center, 6, Weizman Str. Tel-Aviv 64239, Israel)
Purpose: ErbB-4 is a recently described member of the epidermal
growth factor receptor (EGFR) family. Relatively little is known
about the expression of erbB-4 in human tumours. In the present
study we assessed the possible role of c-erbB-4 expression product
as a tissue marker for STS, and its correlation with the response to
chemotherapy. Patients: The histological specimen of 29 patients
with STS of a limb who had received preoperative doxorubicin-
based chemotherapy were studied. The extent of tumor necrosis
was evaluated histologically. Paraffin blocks of preoperative inci-
sional biopsy were available for immune staining (avidin-biotin-
peroxidase technique) from 29 patients, and blocks of the surgical
specimen  after pre-operative chemotherapy were available  from
27.  Results: The objective response rate to preoperative chemo-
therapy was 34%. Wide resection of the tumor was feasible in 12
patients, marginal resection in 14 cases, amputation in 2 patients
with disease progression, and no surgery in one case. The tumor
necrosis was above 90% in 9 patients, 60–90% in 12, and less than
60%  in  7  patients.  It  was  found  that  an  increase  in  C-erbB-4
expression was more common in cases with no response to chem-
otherapy, while no change of or decrease in C-erbB-4 was more
common in responsive tumours (p = 0.004). No correlation could
be found between the degree of necrosis or the chemotherapeutic
regimen and the change in expression of c-erbB-4. The median
DFS was longer for patients with a decrease or no change in expres-
sion of C-erbB-4 than for patients with increased expression.
Discussion: It is believed that post chemotherapy new expression
or no down-regulation of the erbB-4 molecule represents tumor
aggressiveness and increased capability of growth and spread.
Expression of CD44 in Ewing’s sarcoma
A.  AFENYI-ANNAN,  M.D.,  M.A.  RUBIN  &  A.F.G.
PAULINO, M.D.
(University of Michagan Hospitals, Ann Arbor, Michigan, USA)
Purpose: CD44, a transmembrane glycoprotein, has been impli-
cated  in  tumourigenesis  and  metastasis  in  carcinoma.  It  may
potentially  be  a  diagnostic/prognostic  marker  and/or  target  for
cancer therapy. Expression of CD44 has been described in soft
tissue sarcomas but not in Ewing’s sarcoma. We studied the use of
CD44, a hyaluronidase receptor, as a marker for Ewing’s sarcoma
and correlated expression with clinical outcome.
Patients: Surgical  pathology  and  clinical  follow-up  from  55
patients  with  Ewing’s  sarcoma  at  our  institution  between
1987–2000  was retrospectively reviewed. Cases with insufficient
tumor material were excluded from the study.
Methods: Microscopic slides from 67 cases of Ewing’s sarcoma
were stained with monoclonal antibodies for MIC-2 (CD99) and
standard CD44 using routine immunohistochemical (IHC) tech-
niques.  The  majority  of  cases  were  stained  in  triplicate  from
different tumor samples.
Results  and  Discussion: The  presence  of  Ewing’s  sarcoma  was
confirmed by MIC-2 (CD99) positivity in 98.5% (66/67) of cases.
CD44 expression was seen in 88% (59/67) of cases with an intense,
membranous staining pattern. CD44 expression did not correlate
with age, sex, and tumor site. Furthermore, there was no statistical
significance  between patient  survival and histologic  response to
preoperative chemotherapy and CD44 expression.
IHC staining  for MIC-2  (CD99) remains  the  gold  standard in
confirming the diagnosis of Ewing’s sarcoma. However, Ewing’s
sarcoma  clearly  expresses  the  standard CD44  antigen.  Further
studies  are needed to determine  how CD44  and/or its  variants
affect growth, metastasis, and prognosis in Ewing’s sarcoma.
Post-chemotherapy tumor necrosis in Ewing’s sarcoma: the
Huvos and Picci Grading Systems Revisited
A. AFENYI–ANNAN, M.A. RUBIN & A.F.G. PAULINO
(University of Michigan Hospitals, Ann Arbor, Michigan, USA)
Purpose: This study compares the two common grading schemes
used to assess tumor necrosis in patients with Ewing’s sarcoma
treated  by  a  combination  of  pre-operative  chemotherapy  and
surgical resection and relates these systems with patient outcome.
The chemotherapeutic response is measured based on necrosis as
a  percentage  of  tumor  volume  (Huvos  system)  or  on  defined
microscopic guidelines, not volume dependent (Picci system). The
ability to predict patient outcome based on the post-chemotherapy
tumor  necrosis  in  resection  specimens  is  well  established  in
patients with osteosarcoma but less so in Ewing’s sarcoma.
Patients: Thirty  patients  with  Ewing’s  sarcoma  treated  with
chemotherapy followed by surgical  resection  between 1987  and
2000 were evaluated. The median age was 14.5 years (range, 3 to
55 years). The male to female ratio was 1.5:1. Tumor location
included both skeletal (24) and extra-skeletal (6) sites.
Methods: Microscopic slides were reviewed and evaluated based
on the two systems of post-therapy tumor necrosis. Results were
stratified into Grades I-IV (Huvos system) and Grades I-III (Picci
system) and compared with patient outcome.
Results  and  Discussion: Post-chemotherapy  tumor  necrosis  in
Ewing’s sarcoma was not an independent prognostic factor in our
series. Survival rates for each grade between systems were compa-
rable (i.e. Huvos grades III-IV and Picci grade III). No statistical
significance between assessment schemes was identified. Neither
system of assessing response to therapy was better at predicting
patient outcome.
An analysis of late events and outcome of localised ewing’s
sarcoma of bone in  patients  with a minimum of 10  years
follow-upEORTC Abstracts 183
A. ABUDU, R.J. GRIMER, S.R. CARTER, R.M. TILLMAN,
P.B.  PYNSENT,  A.M.  DAVIES,  D.C.  MANGHAM  &  D.
SPOONER
(Royal Orthopaedic Hospital Birmingham, UK)
Purpose: To study the long-term outcome, risk of late events and
risk factors for survival and local control in patients with Ewing’s
sarcoma of bone without identifiable metastases at diagnosis.
Patients/Subjects: 95  patients  with  localized  primary  Ewing’s
sarcoma of bone with minimum of 10 years follow-up and treated
with  the  same  protocol  were  studied.  All  received  neoadjuvant
chemotherapy according to UKCCSG protocol. Local treatment
was surgical excision in 60, surgical excision and radiotherapy in
20, and radiotherapy in 15 patients.
Results: 10-year overall and metastases free survival was 60% and
55% respectively. Local recurrence occurred in 10 patients and
was dependent on location of tumour and surgical margins. There
was a significant relationship between local recurrence and metas-
tasis. 14% of metastases occurred after 5 years follow-up and was
seen up to 10 years from diagnosis but not beyond.
Survival was dependent on age at diagnosis, post-chemotherapy
necrosis and development of local recurrence on multivariate anal-
ysis.
Discussion: Development  of  local  recurrence  was  ominous.
Surgical treatment of tumours instead of radiotherapy had a signif-
icant influence on outcome in patients with extremity tumours but
not in those with pelvic tumours. Patients with Ewing’s sarcoma
remain at risk of disease recurrence in the first 10 years of diagnosis
and are probably  cured of disease  after more  than 10  years  of
continuous  disease  free  period.  The  risk  of  radiation-induced
sarcoma in patients managed on a modern radiotherapy protocol
is low in the short term.
Concurrent  conformal  radiotherapy  (CRT)  and  chemo-
therapy in patients with primitive neuroendocrine tumours
(PNETs), ewings sarcoma and leiomyosarcoma.
J. ABRAHAM; C. COLES; N. BURNET & H.M. EARL
(Addenbrookes Hospital, Cambridge)
Purpose: Does  conformal  radiotherapy  (CRT)  reduce  acute
toxicity  and prevent treatment  delays for both modalities  when
using concomitant chemoradiotherapy.
Method: 6patients  (3Ewings, 2PNETs  and 1Leiomyosarcoma)
treated  between  11/96–05/00.  Median  age  27  (range  16–60),
male:female  ratio  5:1.  Locations:  Pelvis(2);  Chest  wall(2);
Femur(1); Thigh(1). 1patient had lung metastases at diagnosis.
Chemotherapy  regimens:  EVAIA  (2/2PNETs)  and  VAIA  (1/
3Ewings)  from  EICESS  ’92  study;  VIDE/VIA  (2/3Ewings)
standard  arm  of  Euro-Ewings  ’99  protocol;  VIA
(1Leiomyosarcoma).  2  or  more  cycles  of  chemotherapy  were
administered  concurrently  with  CRT.  CRT  was  given  as  per
EICESS ’92 protocol, except the Leiomyosarcoma patient. CRT
reduces  volume  of  normal  tissue  irradiated  including  bone
marrow. Case notes were reviewed for treatment delays and acute
toxicities. Additional toxicity data were available from standard-
ised flow charts (4/6patients).
Results: 4/6patients  achieved  all  scheduled  treatments  without
delay.  Neutropenic  sepsis  delayed  1  chemotherapy  cycle  (1/
6patients) and the start of CRT (1/6patients). Grade3 toxicities
included oral mucositis (2/6patients), vomiting (1/6patients), and
neutropenic  sepsis  (3/6patients).  Grade4  neutropenic  sepsis  (1/
6patients).  There  were  no  acute  radiotherapy  toxicities.  5/
6patients required 10–25% dose reductions and GCSF.
Discussion: Our experience  suggests  CRT facilitates  scheduled
delivery  of  chemoradiotherapy  and  reduces  acute  toxicities
compared with conventional radiotherapy. 4/6patients achieved all
scheduled  treatments.  Standardised  forms  improved  toxicity
assessment  accuracy.  Optimal  treatment  schedules  allow  dose-
dense  chemotherapy  and  potentially  increased  tumour  kill  by
combined chemoradiotherapy. We hope this will give better overall
survival and increased local control. We plan a 20patients phase II
pilot  study  of  concurrent  chemotherapy/CRT  with  primary
endpoints of local recurrence and overall survival.
Peripheral  primitive  neuroectodermal  tumor/ewing’s
sarcoma of the meninges. A report of two cases.
R. SCIOT, C. GIANINI* & A.P. DEI TOS*
(Department of  Neuropathology, University  Hospital  K.U.  Leuven,
Leuven, Belgium,* Department of Pathology, Regional Hospital Trevi-
so, Italy)
Purpose: To report on  the  occurrence of  a primary peripheral
primitive  neuroectodermal  (PNET)  in  the  meninges  of  two
patients.
Patients: The first patient was 17 year old boy with a frontal, dura
based tumor. The second patient, a 12 year old boy, presented
with a dura attached parietal parasagittal mass. There was no bone
involvement and no primary tumor/metastases could be detected
outside the CNS. Both tumors were resected and both patients
received chemo-, and radiotherapy.
Results: Compact nests of uniform ‘small blue round cells’ were
seen in both lesions. On immunohistochemistry, a strong CD99
and vimentin expression was seen. Synaptophysin, neurofilament,
Epithelial Membrane Antigen, cytokeratin, and GFAP were nega-
tive. A t(11;22)(q24;q12) could be demonstrated with RT-PCR in
case 1 while FISH analysis showed a rearrangement of the EWS
gene on 22q12 in case 2. The CD99 expression, as well as the
molecular findings indicate that both lesions represent a peripheral
PNET.
Discussion: Meningeal  peripheral  PNET  is  extremely  rare  as
evidenced by the presence of only one reported case with proven
t(11;22)(q24;q12). The result of this translocation is a fusion of
the  EWS  gene  (22q12)  with  a  truncated  transcription  factor
FLI1(11q24), resulting in an oncogenic conversion of the EWS
gene.  These  molecular  findings  clearly  differ  from  the  central
PNET,  in  which  an  isochromosome  17(q)  is  characteristically
found, mainly in medulloblastoma. In addition to immunohisto-
chemistry, detection of the t(11;22)(q24;q12) is extremely useful
to discriminate peripheral PNET from a central PNET, which is
much more common in this location.
Activation  of  peroxisome  proliferation  activated  receptor
induces survival of human osteosarcoma cells.
E. LUCARELLI, L. SANGIORGI, V. MAINI, J. WARZECHA
& P. PICCI
(Istituto Ortopedici, Bologna, Italy)
Purpose: Because activation of PPAR has been shown to promote
apoptosis in several tumor cell lines, in this study we investigated
whether  PPAR   activation,  stimulated  by  torglitazone  (TZD),
induced apoptosis in a human osteosarcoma (OS) cell lines that
expresses PPAR.
Subject: PPAR  is a member of the nuclear receptor superfamily.
PPAR_  binds  to  the  promoter  region  of  a  target  gene  as  an
heterodimer with the retinoid X receptors (RXR). Several natural
and synthetic ligands bind to PPAR  such as the natural occurring
15-deoxy  12, 14 prostaglandin J2 and fatty acids derivatives and
the synthetic class of drug thiazolidinediones (TZDs).
Results: In our experiments, TZD treatment never induced apop-
tosis of OS cells;  on the contrary, TZD increased cell  number,
based on MTT proliferation assay. Remarkably, the TZD-induced
increase in cell number depended on a decrease of apoptosis that184 EORTC Abstracts
naturally occurred in the culture and was not due to an increased
cell  proliferation  rate.  TZD  prevented  apoptosis  also  when
induced by staurosporin. The TZD-mediated survival effect corre-
lated with the activation of Akt, a well known mediator of survival
stimuli.
Discussion: Our results suggest that PPAR  activation may be a
key element that inhibits cell death and promotes tumor growth.
Results from this study caution against the use of PPAR_chemical
agonist on patients with OS and suggest that PPAR  activation by
natural ligands may be a key step in OS development.